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Abstract——63,4-Methylenedioxymethamphetamine
(MDMA) isasynthetic,psychoactivedrug that isprimarily
used recreationally but also may have some therapeutic
value. At low doses, MDMA produces feelings of re-
laxation, empathy, emotional closeness, and euphoria.
Higher doses can produce unpleasant psychostimulant-
and hallucinogen-like adverse effects and therefore
areusuallynot taken intentionally. There is considerable
evidence that MDMA produces neurotoxicity and
cognitive deficits at high doses; however, these findings
may not generalize to typical recreational or therapeutic
use of low-dose MDMA. Here, we systematically review
25 years of research on the cognitive effects of MDMA
in animals, with a critical focus on dose. We found no
evidence that doses of less than 3 mg/kg MDMA—the
dose range that users typically take—produce cognitive
deficits in animals. Doses of 3 mg/kg or greater, which
were administered most often and frequently ranged
from 5 to 20 times greater than an average dose, also
did not produce cognitive deficits in a slight majority
of experiments. Overall, the preclinical evidence of
MDMA-induced cognitive deficits is weak and, if
anything, may be the result of unrealistically high
dosing. While factors associated with recreational
use such as polydrug use, adulterants, hyperthermia,
and hyponatremia can increase the potential for
neurotoxicity, the short-term, infrequent, therapeutic
useofultra low-doseMDMAisunlikely topose significant
cognitive risks. Future studies must examine any
adverse cognitive effects of MDMA using clinically
relevant doses to reliably assess its potential as a
psychotherapeutic.
I. Introduction
“Solely the dose determines that a thing is not a
poison.” – Paracelsus
63,4-Methylenedioxymethamphetamine (MDMA,
known as Ecstasy or Molly; Fig. 1) is a synthetic,
psychoactive drug that is usually described as having
mixed psychostimulant- and hallucinogen-like effects
(i.e., effects like amphetamine and lysergic acid
diethylamide) (Green et al., 2003). As with other
phenethylamine and cathinone stimulant-psychedelics,
MDMA primarily increases the neurotransmission of
serotonin (5-HT) in the brain, specifically by reversing
the 5-HT reuptake transporter (SERT) and causing the
calcium-independent release of 5-HT (Rudnick and Wall,
1992; Wichems et al., 1995). MDMA also reverses the
dopamine and norepinephrine transporters but to a lesser
degree than SERT (Battaglia et al., 1988). These changes
in brain chemistry produce desirable effects of relaxa-
tion, euphoria, arousal, and increased sociability as well
as potential adverse effects such as nausea, headache,
hallucinations, agitation, and palpitations. As dose is
increased, MDMA produces more adverse effects and
fewer desirable effects (Baylen and Rosenberg, 2006;
Brunt et al., 2012), and therefore it is unlikely that
MDMA is used intentionally at atypically high doses.
As such, at thedoses people typically take (i.e., 75–125mg,
see section II.A),MDMAprimarily produces effects unlike
classic psychostimulants or hallucinogens (Nichols, 1986).
MDMA is usually described by its proponents as an
“empathogen-entactogen”—a drug that increases em-
pathy and closeness, both emotional and physical. It is
these latter effects that are of significant therapeutic
interest and are not shared with psychostimulants or
hallucinogens.However, considerable evidence thatMDMA
is neurotoxic at high doses (see section III) has given
considerable pause to this therapeutic interest.
Although MDMA is frequently described as the pro-
totypical “designer drug,” MDMA was synthesized and
patented byMerck in 1912 as an unimportant precursor
in a new chemical pathway (Freudenmann et al., 2006).
The compound was shelved until Alexander Shulgin
“rediscovered” MDMA in the 1970s. Shulgin produced
the first reports on the psychoactive effects of MDMA
and promoted its use as an adjunct to psychotherapy
(Shulgin and Nichols, 1978). It was not until the early
1980s that MDMA began to be used recreationally, often
at nightclubs, dance parties, and raves (Weir, 2000). The
growing popularity of MDMA, in addition to new re-
search findings on its adverse effects, led the U.S. Drug
Enforcement Administration to classify MDMA as a
Schedule I drug in 1985 for having “high abuse potential
and no medical value” (Lawn, 1985, 1988; Shulgin, 1986).
Despite its illegality, the recreational use of MDMA
steadily increased through the 1990s with the rise of
the underground rave scene (Schwartz and Miller,
1997) and plateaued in the early 2000s (Schulenberg
et al., 2018). Any current increase in MDMA use may
be related to the emergence of electronic dance music
intomainstream culture (Fraser, 2012). Recently, scientific
interest in the potential therapeutic value of MDMA has
re-emerged as the result of findings that MDMA-assisted
psychotherapy may be effective for treatment-resistant
post-traumatic stress disorder (Bouso et al., 2008;
Mithoefer et al., 2011, 2013, 2016; Oehen et al., 2013).
ABBREVIATIONS: 5-CSRT, 5-choice serial reaction time; CWM, Cincinnati water maze; DA, delayed alternation; DMS, delayed matching-
to-sample; DNMS, delayed nonmatching-to-sample; FC, fear conditioning; 5-HT, serotonin; MDMA, 63,4-methylenedioxymethamphetamine;
MWM, Morris water maze; NOR, novel object recognition; NPR, novel place recognition; OST, odor span task; PA, passive avoidance; RAM,
radial arm maze; SA, spontaneous alternation; SD, spatial discrimination; SERT, serotonin transporter; SR, social recognition.
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The United States “Monitoring the Future” national
survey indicates that the lifetime prevalence of MDMA
use among young adults (19–28 years of age) has
remained relatively stable since 2000 (about 13%) and
is significantly higher than in the 1990s (about 5%)
(Schulenberg et al., 2018). Most MDMA users consume
the drug relatively infrequently and only for a few years
in their early twenties (Green et al., 2003; Kuypers
et al., 2016). The 2016 U.S. National Survey on Drug
Use andHealth revealed that about one-third of lifetime
MDMA users aged 18–25 years had used the drug in the
past year, while less than 8% of lifetime MDMA users
aged 26 years and older had used the drug within the
past year (Center for Behavioral Health Statistics and
Quality, 2016). Despite the low exposure, the long-term
effects of MDMA use in young adulthood are a signifi-
cant concern and one that is especially relevant to the
current young adult population.
As both recreational and therapeutic interest inMDMA
has increased over the past 40 years, so have concerns
regarding the possible harmful effects of MDMA. There
is evidence from both human and animal research that
MDMA produces neurotoxicity and cognitive deficits.
This evidence, however, is controversial and may have
resulted from experiments with methodology that fail
to generalize to typical MDMA users. The validity of
MDMA toxicological findings rests particularly with
respect to self-reported drug use and other confounding
variables in human studies, the doses administered in
animal studies, and the ability to generalize findings
from animals to humans. Dose is a determinant of
toxicity for virtually any substance, as even water and
oxygen produce adverse effects and can lead to death at
high doses. The question of critical importance then is:
do the doses typical users actually take actually pro-
duce cognitive deficits and/or neurotoxicity? This ques-
tion becomes even more acute when one considers that
therapeutic dosing may be even lower than recreational
dosing, meaning that MDMA could have therapeutic
value at doses far below those for which any evidence of
toxicity exists.
Others have extensively reviewed findings on the
cognitive and neurotoxic effects of MDMA in humans as
well as the neurotoxic effects of MDMA in animals (e.g.,
Baumann et al., 2007; Zakzanis et al., 2007; Mueller
et al., 2016). In this paper, we summarize these review
articles and discuss some potential methodological issues.
Our aim is to provide the first ever full systematic review
of findings on the cognitive effects of MDMA in animals.
We review these studies with a critical focus on dose.
II. 63,4-Methylenedioxymethamphetamine Dose
A. Human Use
MDMA is almost exclusively administered as a race-
mic mixture, although there is evidence that its two
enantiomers have different pharmacological and be-
havioral effects (Fantegrossi, 2008; Pitts et al., 2018).
MDMA is commonly sold as a tablet (i.e., “Ecstasy”;
Fig. 2) or as crystalline powder (loose or in a capsule,
i.e., “Molly”; Fig. 3) and is usually ingested orally;
however, crushed tablets or crystalline powder can
also be taken sublingually, buccally, or intranasally
(Eisner, 1989). Because pure MDMA cannot be made
into a pressed tablet by itself, Ecstasy tablets contain
other substances, including excipients such as cellu-
lose and often other active agents such as stimulants
or other MDMA-like substances. “Molly” is often per-
ceived by the purchasers to be pure MDMA, but is
also frequently contaminated with other cheaper or
more accessible substances (Palamar, 2017). Based
on EcstasyData.org, an independent laboratory testing
service for streetMDMA, only 43.7%of the 4063 samples
tested between 1996 and 2017 contained only MDMA.
The remaining samples contained either MDMA with
additional substance(s) (18%) or no MDMA (39%) (Fig. 4).
Therefore, only 62% of street MDMA truly contained any
MDMA, and 57% of street MDMA consisted partially or
entirely of other substances (often a cocktail of substances).
The most common substances mixed with or sold as
MDMA included stimulants (55%; e.g., caffeine, metham-
phetamine, trifluoromethylphenylpiperazine, benzyl-
piperazine, pseudoephedrine), MDMA-like substances
Fig. 2. MDMA in the form of “Ecstasy” tablets (http://www.usdoj.gov/dea/
programs/forensicsci/microgram/mg0103/mg0103.html, Open Source).
Fig. 1. Chemical structure of 63,4-methylenedioxymethamphetamine
(MDMA) (https://chem.nlm.nih.gov/chemidplus/name/mdma%20hcl,
Open Source).
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(20%; e.g., methylenedioxyamphetamine,methylenediox-
yethylamphetamine, methylone), and/or dissociatives
(11%; e.g., dextromethorphan, ketamine) (https://
www.ecstasydata.org/stats.php).1 It is important to note
that the samples from EcstasyData.org are voluntarily
submitted and are not a random sampling of available
street MDMA. Nevertheless, given that the available
data shows that more than half of street MDMA is
adulterated and almost half of street MDMA does not
contain any MDMA, MDMA users have most likely
consumed these other psychoactive substance(s) in
addition to and/or instead of MDMA.
MDMA users most commonly take doses of about
75–125 mg, or about 1 to 2 mg/kg, while doses higher
than 200 mg are usually unintentional because they
can produce unpleasant adverse effects, including hy-
perthermia and paranoia (https://erowid.org/chemicals/
mdma/mdma_dose.shtml; Hayner andMcKinney, 1986;
Green et al., 2003; Gouzoulis-Mayfrank and Daumann,
2006; Morgan, 2000; Ricaurte et al., 2000). Consistent
with this, Brunt et al. (2012) revealed that doses of
81–100 mg MDMA are associated with the highest
probability of experiencing desirable subjective effects,
while doses greater than 160 mg MDMA lead to more
adverse than desirable effects. Analyses of streetMDMA
contents indicate that tablets usually contain doses in
the range of those commonly used, yet there are some
variations by batch and location. Older reports have
suggested that MDMA tablets contain 70–120 mg on
average (Parrott, 2004). Several more recent large-scale
analyses in various countries indicated that MDMA
tablets contain average doses of about 66–87 mg (close
to 1 mg/kg) (Giraudon and Bello, 2007; Vogels et al., 2009;
Brunt et al., 2012; Vidal Giné et al., 2016). Data from
the 2016 European Drug Report indicated that tablets
typically contain between 68 and 95 mg of MDMA (also
close to 1 mg/kg) (EMCDDA, 2016).
MDMA users usually take one to two tablets per
occasion and generally use MDMA once per week or
less because of rapid tolerance to its desirable effects
(Topp et al., 1999; Morgan, 2000; Winstock et al., 2001;
Riley et al., 2001; Scholey et al., 2004; Gouzoulis-Mayfrank
and Daumann, 2006; Parrott et al., 2006; ter Bogt et al.,
2006). Only about 9%–17% of MDMA users take an
average of three or four tablets per occasion, and about
3%–10% of MDMA users take an average of more than
four tablets per occasion (Scholey et al., 2004; Parrott
et al., 2006; ter Bogt et al., 2006). Because each tablet
is expected to have a dose of about 1 mg/kg, a typical
weekly dose of two tablets is about 2 mg/kg, but heavier
users may be taking weekly doses of 3 mg/kg or more. In
our review, we focus on understanding typical recrea-
tional MDMA users rather than atypical heavy users.
The therapeutic doses of MDMA used in current
clinical trials are comparable to typical recreational
doses yet are administered on only a few separate
occasions. In the two completed phase 2 clinical trials
testing MDMA-assisted psychotherapy for treatment-
resistant post-traumatic stress disorder, patients were
treated with a dose of 125 mg MDMA, plus a 62.5 mg
supplemental dose in some cases, on two or three
occasions (Mithoefer et al., 2011; Oehen et al., 2013).
MDMA may potentially have therapeutic value at even
lower doses, and we encourage investigators to explore
those doses.
In summary, relatively low doses (,3mg/kg) are used
both therapeutically and recreationally. However, it is
critical to differentiate between the therapeutic use of
Fig. 3. MDMA crystalline powder in capsule form, commonly referred to
as “Molly” (https://commons.wikimedia.org/w/index.php?curid=1884576,
Open Source).
Fig. 4. Contents of 4063 samples of street MDMA tested by EcstasyData.org
and other organizations between 1996 and 2017. Samples sold as MDMA
contained either MDMA only, MDMA in combination with other substances,
or no MDMA at all. Less than half of street MDMA samples contained
MDMA only and more than half of street MDMA samples consisted partially
or entirely of other substances (original figure; data redrawn with permission
from https://www.ecstasydata.org/stats.php).
1The values for this analysis were obtained from the Test Result
Statistics: Summary Data on EcstasyData.org (Display as: Numbers;
By date: Tested; Uncheck: EcstasyData Only). We included the laboratory
testing results for all samples sold as MDMA between 1996 and 2017,
which is listed as the total number of samples containing 1) MDMA
Only, 2) MDMA + Something, or 3) No MDMA. Most of the samples
(about three-fourths) were submitted from the United States. This
analysis was conducted on 05/04/2017 and therefore includes all
laboratory testing results up to that date.
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pure MDMA in controlled medical settings and the
recreational use of potentially impure MDMA in poten-
tially high-risk settings. Our systematic review of
preclinical MDMA research speaks to the use of pure
MDMA in therapeutic settings or low-risk recreational
settings.
B. Animal to Human Scaling
There has been significant controversy regarding
whether the doses of MDMA administered to animals
in preclinical studies accurately reflect those taken by
human users. Given the average human weight of 70 kg,
a typicalMDMAdose of 75–125mg is equivalent to about
1 to 2 mg/kgMDMA. Despite this, the majority of animal
studies administer doses ranging from 10 to 20 mg/kg,
which is equivalent to 700–1400 mg in a 70-kg human
and is about 5–20 times larger than a typical MDMA
dose.
Early MDMA researchers argued that the method of
“interspecies scaling” (Mordenti and Chappell, 1989)
should be used to translate MDMA doses across species
(Ricaurte et al., 2000;McCann andRicaurte, 2001). This
method proposes that smaller animals require much
larger doses than humans, using the equation Dhuman =
Danimal  (Whuman/Wanimal)0.7, where D is drug dose in
milligrams, W is body weight in kilograms, and 0.7 is
the “allometric constant” that accounts for differences in
drug elimination. As a result, a dose of 98 mg in a 70 kg
human (1.4 mg/kg) was equated to 7 mg/kg in rats and
5 mg/kg in monkeys. Most the studies reviewed here
argued that doses of 10–20 mg/kg in rodents are suitable
for modeling recreational use of MDMA, as they trans-
late to a human dose of 140–280 mg under “allometric
scaling.” Allometric scaling results in animal doses that
are exceedingly higher than those determined by a
simple conversion of dose based on body weight, and the
approach is not without controversy.
We have typically argued that one-to-one dosing should
be used, unless further specific knowledge (for example,
metabolic or actual exposure data) justifies some specific
kind of alternative scaling (Shuman et al., 2009; Wood
et al., 2014; Carmack et al., 2014). Furthermore, although
doses vary somewhat in veterinary medicine, across
a wide variety of indications, most drugs are given
roughly on the same scale as human doses converted
on a straight milligrams per kilogram basis. For example,
fluoxetine dosing in dogs and cats is 1 to 2 mg/kg (https://
www.reconcile.com/pdfs/prescribing-information.pdf),
which is quite similar to human dosing (http://pi.lilly.com/
us/prozac.pdf).
More recently, several researchers have argued that
allometric scaling is not a valid approach for MDMA
research. Specifically, this method does not take prin-
ciples of pharmacokinetics/pharmacodynamics into ac-
count. Green et al. (2009, 2012a) explain that factors
such as bioavailability, active metabolites, plasma pro-
tein binding differences, and patterns of systematic
exposure are critical influences on drug effects, and
these factors can vary markedly between species and
methods. Humans almost always ingest MDMA orally,
whereas animals are administered MDMA intraperito-
neally or subcutaneously, which may lead to significant
differences in bioavailability and/or metabolism (Green
et al., 2009, 2012a). In humans, there is a nonlinear
relationship between dose and plasma concentration
such that a twofold increase in dose (from 1 to 2 mg/kg)
results in a fourfold increase in plasma concentration,
while the relationship between dose and plasma con-
centration in rats is approximately linear. As a result,
the dose-plasma concentration curves of humans and
rats are comparable at doses below 2.5 mg/kg but differ
drastically at higher doses (Green et al., 2009, 2012a).
Specifically,Cmax (peakplasma concentration) of 1.6mg/kg
MDMA (orally) in humans and 2 mg/kg MDMA (in-
traperitoneally and subcutaneously) in rats is similar
[humans (oral): 292 6 76 ng/ml, rats (intraperitoneal):
210 6 108 ng/ml, rats (subcutaneous): 196 6 50 ng/ml).
Time of drug peak, however, is much shorter in rats
[0.14 6 0.08 hours (intraperitoneal), 0.75 6 0.29 hours
(subcutaneous)] than in humans [2.46 0.6 hours (oral)]
(Kolbrich et al., 2008; Baumann et al., 2009). Thus,
testing rats 10–45 minutes after parenteral doses of
about 2 mg/kg is roughly equivalent to peak exposure
in humans 2.4 hours after taking about one and a half
oral tablets. The differences in time course are because
MDMA is absorbed and metabolized much faster in
rats than in humans and the proportion of metabolites
formed differs strikingly between species (Green et al.,
2009, 2012a). This is a major concern because the active
metabolites of MDMA, rather than MDMA itself, appear
to be responsible for long-termneurotoxicity. For instance,
methylenedioxyamphetamine, an active and neurotoxic
metabolite of MDMA, accounts for 23%–34% of MDMA
metabolism in rats but only about 10% in humans (Green
et al., 2012a). Nonetheless, MDMA is extensively me-
tabolized in both animals and humans, a condition under
which the allometric relationship does not hold true
(Lin, 1998; Baumann et al., 2007).
For the reasons above, as well as others extensively
discussed byBaumannet al. (2007) andGreen et al. (2009,
2012a), allometric scaling in MDMA research is arguably
flawed, and findings under this method should be inter-
preted with caution for using excessive dosing. Baumann
et al. (2007) proposes the alternative method of “effect
scaling” for extrapolating doses between species. Under
this method, animal doses are determined based on the
lowest dose of drug that produces a specific pharmaco-
logical response in animals and humans. Doses of about
1 to 2 mg/kg MDMA produce equivalent pharmacology
effects in humans (orally) and rats (intraperitone-
ally, subcutaneously, or intravenously), including the
in vivo release of serotonin and dopamine [humans
(oral): 1.5 mg/kg, rats (intraperitoneal): 2.5 mg/kg,
rats (subcutaneous): 1 mg/kg], secretion of prolactin and
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glucocorticoids [humans (oral): 1.5 or 1.67 mg/kg, rats
(intraperitoneal): 1–3mg/kg], drugdiscrimination [humans
(oral): 1.5 mg/kg, rats (intraperitoneal): 1.5 mg/kg], and
drug reinforcement [humans (oral): 1 to 2 mg/kg, rats
(intravenous): 1 mg/kg) (Baumann et al., 2007). Unlike
Green et al.’s findings, Baumann et al. (2009) found that
the pharmacokinetics of MDMA are not only nonlinear in
monkeys and humans but also in rats. Regardless of this
discrepancy, it is agreed that the pharmacokinetics of doses
of about 1 to 2 mg/kg MDMA are similar across species.
Because the pharmacologically relevant doses of MDMA
are similar across species, there is not adequate scien-
tific justification for using interspecies scaling to “adjust”
MDMA doses (Baumann et al., 2007, 2009). This is
especially true when considering toxicology, because most
of the “adjustments” have been radical increases in dose,
which tend to suggest a drug is more toxic than it actually
is. Indeed, one might think this could impose a bias in
“finding” toxic effects in drugs of abuse, in general.
Given that doses of about 1 to 2mg/kgMDMAproduce
similar pharmacokinetic, pharmacological, and psycho-
active effects across species and are analogous to the
doses taken by human MDMA users, these low doses
should be used in preclinical MDMA research in the
absence of explicitly justified interspecies scaling.While
low doses are unlikely to produce neurotoxicity, they
may still have adverse cognitive effects (Green et al.,
2012a,b). A central aim of this review is to determine if
MDMA influences cognitive functioning at these doses.
III. Neurotoxicity in Animals and Humans
The long-term neurotoxic effects of MDMA have been
studied extensively in animals and humans. Ricaurte
et al. (2000), Green et al. (2003), and Lyles and Cadet
(2003) were among the first to review the many findings
on MDMA-induced neurotoxicity in animals. Research
in rats and non-human primates demonstrated that
MDMA produces significant reductions in biochemical
markers of serotonergic activity that last for months to
years. The most prominent reductions include decreased
levels of 5-HT and 5-hydroxyindoleacetic acid (the major
metabolite of 5-HT), decreased numbers of SERT, and
decreased activity of tryptophan hydroxylase (the rate-
limiting enzyme in 5-HT synthesis). Additional studies
found through histologic methods (e.g., silver staining)
that MDMA produces degeneration of 5-HT axons and
terminals. These findings suggest that the long-lasting
and selective serotonergic biomarker reductions pro-
duced by MDMA may reflect neurodegeneration. How-
ever, as with amphetamine neurotoxicity, there is no
evidence of actual cell death.
These early studies usedMDMA doses that are exceed-
ingly large and not representative of those taken by
typical users (as was done in early amphetamine neuro-
toxicity studies). Most rat strains (e.g., Lister Hooded,
Sprague-Dawley, and Wistar) typically require several
MDMA doses of 20 mg/kg or more to exhibit serotonergic
deficits (Colado et al., 1993;Aguirre et al., 1998; Shankaran
and Gudelsky, 1999; Green et al., 2003). Non-human
primates show higher sensitivity to MDMA-induced
serotonergic deficits, as doses of about 5 mg/kg will
produce deficits that are more severe than those observed
in rats (Ricaurte et al., 1988; Ricaurte andMcCann, 1992;
Green et al., 2003). Mice are far less sensitive than rats
to MDMA-induced serotonergic deficits, as doses of up
to 50 mg/kg produce only slight deficits (Stone et al.,
1987; Logan et al., 1988; Green et al., 2003). Although
there are differences between species/strains, MDMA-
induced deficits in markers of serotonergic neurons
require fairly high and often sustained dosing (Green
et al., 2003).
In a more recent review, Baumann et al. (2007)
analyzed findings on MDMA-induced neurotoxicity in
rats with respect to dose. Several studies have demon-
strated that behaviorally relevant doses of MDMA (i.e.,
1 to 2 mg/kg; see section II.B) do not produce reductions
in biochemical markers of 5-HT neurons. The doses of
MDMA that do produce serotonergic deficits (i.e., 10–
20 mg/kg) are five or more times greater than behav-
iorally relevant doses of MDMA. Even so, these high
doses are not reliably associated with 5-HT neuron
degeneration. Rather, evenmore extreme doses ofMDMA
were used in the histology studies that found neurotoxic
damage. For instance, massive cumulative doses of 100–
600 mg/kg (i.e., up to 42,000 mg or 600 MDMA tablets
in humans) were given to rats that exhibited increased
silver-positive staining in degenerating 5-HT neurons.
Thus, MDMA-induced reductions in biochemical markers
of 5-HT neurons do not necessarily reflect neurotoxic
damage (see Baumann et al. for additional supporting
evidence). There is insufficient evidence that the MDMA
doses typically used by humans result in serotonergic
neurotoxicity in animal models.
Nevertheless, evidence of possible MDMA-induced
neurotoxicity in animals has raised concern for neuro-
toxicity in human MDMA users. Reneman et al. (2006)
and Cowan (2007) provided reviews on some of the
latest neuroimaging studies in human MDMA users.
While there has beenmuch debate regarding themethods
used in early human studies on MDMA-induced neuro-
toxicity, modern neuroimaging techniques such as pos-
itron and single photon emission tomography provide
updated findings on the effects of MDMA in the human
brain. The most consistent finding is that MDMA users
exhibit a reduction in SERT density that appears to be
associated with the degree of MDMA exposure, while
findings on other serotonergic deficits are largely
inconsistent. It remains unclear whether the SERT
reductions in MDMA users are a direct reflection of
serotonergic neurodegeneration.
A concern regarding the above findings is that
most studies investigated samples of heavy MDMA
users, with a mean lifetime consumption ranging from
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173 to 880 MDMA tablets. Only about 13%–18% of
MDMA users report having takenMDMA onmore than
100 occasions (Scholey et al., 2004; Parrott et al., 2006),
and while this research may be indicative of neurotox-
icity in these heavy users, it is not indicative of the
effects of MDMA in the typical user and is highly
unlikely to reflect patients treated therapeutically
only a few times with MDMA. Mueller et al. (2016)
addressed this issue with a systematic review of neuro-
imaging studies in moderate MDMA users (those with
lifetime use of ,50 occasions or ,100 tablets). The
19 studies that met inclusion criteria provided little, if
any, evidence for brain alterations in moderate MDMA
users.
The animal and human data together suggest that
heavy use of MDMA may produce neurotoxicity, but
typical (i.e., low to moderate) MDMA use may have no
effect on brain structure and function. Human MDMA
research, however, may have issues with experimental
design, confounding variables, andmethodological tech-
niques (explained further in section IV and by Gouzoulis-
MayfrankandDaumann, 2006). In this review,we explore
the functional consequences of MDMA use, specifically
the effects on cognition, as potential indicators of
MDMA-induced neurotoxicity.
IV. Cognitive Effects in Humans
Numerous review articles have evaluated findings
on cognitive functioning in MDMA users. Recent meta-
analyses and systematic reviews suggest that MDMA
users, when compared with drug-naïve or polydrug
controls, are impaired in several cognitive domains
including decision-making (Betzler et al., 2017), atten-
tion (Verbaten, 2003; Zakzanis et al., 2007), executive
functioning (Zakzanis et al., 2007; Murphy et al., 2009;
Roberts et al., 2016), verbal and visuospatial working
memory, short-term memory, and long-term memory
(Verbaten, 2003; Laws and Kokkalis, 2007; Zakzanis
et al., 2007; Murphy et al., 2009, 2012; Nulsen et al.,
2010). Others, however, have found that MDMA users
and controls show no differences in executive switching
(Murphy et al., 2009), executive inhibition (Roberts et al.,
2016), visual short- and long- term memory (Laws and
Kokkalis, 2007), and verbal long-termmemory (Kuypers
et al., 2016). Like the neurotoxicity studies, many of
these reviews include data from heavy MDMA users
only (Verbaten, 2003; Laws and Kokkalis, 2007; Nulsen
et al., 2010; Roberts et al., 2016). Some deficits have
been attributed to polydrug/cannabis use rather than
MDMA use specifically, such as those in decision-making,
visual short-term memory, and verbal long-term memory
(Verbaten, 2003; Nulsen et al., 2010; Betzler et al., 2017),
although there is some evidence of the contrary re-
garding verbal memory (Laws and Kokkalis, 2007).
Overall, the most consistent findings are that heavy
MDMA users exhibit long-term deficits in attention,
executive updating, verbal and visuospatial working
memory, and verbal short-term memory; findings re-
garding other cognitive domains are fairly inconsistent.
Research on the cognitive effects of MDMA in humans
face a multitude of potential methodological issues.
Dose-related, double-blind, placebo-controlled para-
digms are the strongest in human psychopharmacol-
ogy research, but there is a lack of such prospective
studies in MDMA research due to the ethical and legal
barriers of administering MDMA to human volunteers
(Verbaten, 2003). As a result, retrospective cross-sectional
designs dominate in this field, in which a group of self-
reported MDMA users are compared with a control
group. In contrast to prospective designs, retrospective
designs decrease the ability to control potential con-
founds. A potential confounding variable in the studies
reviewed above is that MDMA users are typically poly-
drug users, either knowingly or due to the impurity of
street MDMA. While some studies controlled for self-
reported polydrug use, the contents of impure street
MDMA is typically unbeknownst to all and therefore
cannot be controlled for. Self-reported drug use also
introduces uncertainty in drug use patterns, including
doses, number of exposures, and duration of abstinence.
Another potential issue with retrospective designs is
that the observed effects could be due to pre-existing
differences, such as intelligence, cognitive, psychologic,
neurochemical, genetic, or personality differences in the
selected control group. It is conceivable that individuals
with cognitive deficitsmay bemore likely to useMDMA,
and therefore the cognitive deficits observed in MDMA
users could have been a cause ofMDMAuse rather than
a consequence, although the direction of causality has
been sparsely explored and is still a matter of debate
(Curran, 2000; Roberts et al., 2016; Betzler et al., 2017).
To summarize, there has been consistent evidence of
some cognitive deficits in heavy MDMA users (specifi-
cally in attention, executive updating, workingmemory,
and verbal short-term memory), but we cannot be certain
that these deficits are exclusively due to MDMA use
rather than the use of other drugs, pre-existing condi-
tions, and/or other confounding variables (Curran, 2000;
also discussed further in the reviews/meta-analyses cited
above). It is likely that MDMA poses considerable risk at
high doses, as does high-dose amphetamine. However,
as with amphetamine, low-dose MDMAmay have great
clinical potential and should not be barred based on
unfounded concerns about behavioral or neural toxicity.
V. Cognitive Effects in Animals—
Systematic Review
Because of themethodological issues inhumanMDMA
research, animal models may be ideal for studying the
cognitive effects of MDMA, specifically with respect to
the therapeutic use of pure MDMA. Here we provide the
first systematic review of findings on the cognitive effects
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of MDMA in animal models. A total of 90 experiments
(from 68 articles) provide such findings using a variety
of tasks. We divided research findings by task into five
major cognitive domains: 1) attention, 2) workingmemory,
3) spatial learning and memory, 4) nonspatial learning
and memory, and 5) fear-motivated learning and mem-
ory. Findings on both the on-drug (acute) and post-drug
(long-lasting) effects of MDMA are included. In some
cases, on-drug impairments are associated with task
performance impairments (e.g., impaired movement
or altered state while intoxicated) rather than actual
cognitive impairment. All findings are reviewed with
respect to methodology, with a specific emphasis on
the doses of MDMA administered. Again, we stress that
most of these studies used doses that are exceedingly
higher than low, behaviorally relevant doses of 1 to
2 mg/kg MDMA. The ability to generalize high-dose
($3 mg/kg MDMA) findings to typical MDMA use, and
specifically therapeutic use, is limited.
A. Attention
1. 5-Choice Serial Reaction Time. The 5-choice serial
reaction time (5-CSRT) task (Robbins, 2002) is commonly
used to assess attention and impulsivity in non-human
primates. As to the studies reviewed here, the task is
conducted in an operant chamber that contains amonitor
and a single response lever. On each trial, five circles
connected by lines are presented on the monitor, and
the trial begins when the animal presses and holds
down the response lever. After a variable delay period of
0.75–2.5 seconds, a yellow circle is quickly presented on
one of the five circles for 20, 100, or 1000 milliseconds.
The animal must touch the circle that contained the
yellow circle within 2 seconds for reinforcer delivery.
The release latency (time to release the lever) and
movement time (time to move from lever to target) are
used to measure attentional performance, with longer
release latencies/movement times representing poorer
attention.
Taffe et al. (2001, 2002) investigated the effects of
MDMA on the 5-CSRT task, and these studies are listed
in Table 1. Taffe et al. (2001) trained adult male rhesus
monkeys on the task for 4 weeks prior to drug treat-
ment. Monkeys were then given two daily injections of
10 mg/kg i.m. MDMA at a 12-hour interval for 4 consec-
utive days. Testing continued during the treatment
week (3–5 hours after the first injection of each day, so
testing occurred after the peak drug effect) and also
for the following 21 weeks. During all three testing
periods (pretreatment weeks, treatment week, and
posttreatment weeks), MDMA-treated monkeys and
saline controls did not significantly differ in release
latency ormovement time. However, the release latency
of MDMA-treated monkeys was significantly longer
during the treatment week than during the pretreat-
ment weeks. Taffe et al. (2002) tested the same group
of rhesus monkeys 13 months later, and again MDMA-
treated monkeys and saline controls did not signif-
icantly differ in release latency or movement time.
Together, these findings indicate that treatment with
repeated doses of 10 mg/kg MDMA may produce slight
attentional deficits during the treatment period but
have no residual effects on attention for more than
1 year later.
B. Working Memory
1. Delayed (Non)matching-to-Sample. The delayed
matching-to-sample (DMS) and delayed nonmatching-
to-sample (DNMS) tasks (see Dudchenko, 2004) are
widely used to study working memory in many species,
including rodents, birds, and non-human primates. These
tasks assess recognition memory for a visual stimulus
and can be conducted using stimuli such as retractable
levers, color illuminated keys, or visual stimuli dis-
played on a press-plate or touchscreen. Each trial has
threemainphases: sample presentation, delay, and choice.
During the sample presentation, a single visual stimulus
is presented to the animal (i.e., right or left lever, red or
green key, a geometric shape on the press-plate or
touchscreen). After the animal makes an observing
response (i.e., a press or nose-poke) to the sample stimulus,
the stimulus is removed for a delay period of a specified
duration. The delay period is followed by the choice phase,
when two or three visual stimuli are presented to the
animal, only one of which is identical to the sample
stimulus. The animalmust respond (i.e., a press or nose-
poke) to the sample stimulus in the DMS task or the
novel stimulus in the DNMS task for accuracy, food
reinforcer delivery, and initiation of the next trial.
Sessions are typically conducted daily, and a range of
delay periods are tested, with each animal performing
multiple trials at each delay duration. Accuracy is
TABLE 1
Studies examining the effects of MDMA on attention
Article Taska Subjectsb Doses/Frequencyc Timelined Effectse
Taffe et al., 2001 5-CSRT Monkeys (R), Adult, Male 10 mg/kg (i.m.)  2/day, 4 days Training: Predrug
Testing: On-Drug, Postdrug
↓ (On-Drug), ⌀ (Postdrug)
Taffe et al., 2002 5-CSRT Monkeys (R), Adult, Male 10 mg/kg (i.m.)  2/day, 4 days Training: Predrug
Testing: Postdrug
⌀
aStudies used the 5-choice serial reaction time (5-CSRT) task.
bSpecies (strain), age, and sex of subjects. Strains include rhesus (R) monkeys.
cDose, route, and frequency of MDMA administration. Treatment days/weeks are consecutive unless noted as “spaced.”
dWhen training and testing occurred in relation to drug treatment. Pre- and post-drug training/testing were always conducted off-drug.
eEffects of drug treatment on attention: ⌀ No Effect, ↓ Impairment, ↑ Enhancement.
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determined at each delay by average percent correct
(i.e., percent of trials that a correct response was made).
Under normal working memory function, accuracy will
decrease as the duration of the delay period increases. A
working memory deficit is usually indicated by normal
accuracy under no delay or ultra-short delays but a
significant decrease in accuracy relative to normal at
longer delays. A significant decrease in accuracy relative
to normal across all delays [i.e., no/ultra-short delay(s)
and long delays] does not represent impaired working
memory, but rather a performance impairment.
Table 2 includes the seven studies that tested the
effects of MDMA on the DMS (5 studies) and DNMS
(2 studies) tasks. All of these studies trained animals
on the task to a criterion level before beginning on-drug
testing, and some of the studies continued testing after
the on-drug trials.
Harper et al. (2005) and Harper (2011) trained and
tested adult male Sprague-Dawley rats on a DMS task
using retractable levers and delays of 0.1, 3, 9, and
18 seconds. Harper et al. (2005) gave rats 0, 0.3, 1, 2,
or 3 mg/kg i.p. MDMA in a within-subjects design
10 minutes before on-drug test sessions. Relative to
saline, doses of 0.3 and 1 mg/kg MDMA had no effect
on accuracy, and doses of 2 and 3 mg/kg MDMA signifi-
cantly decreased accuracy across all delays. Harper (2011)
gave rats 0 or 3 mg/kg i.p. MDMA in a within-subjects
design 5 min before on-drug test sessions. A dose of
3 mg/kg MDMA significantly decreased accuracy across
all delays relative to saline. Together, these results indi-
cate that while doses of 2 and 3 mg/kg MDMA impair
performance on the task, doses of 0.3, 1, 2, and 3 mg/kg
MDMA have no effect on working memory.
Frederick et al. (1995a) trained and tested adult male
rhesus monkeys on a DMS task using a press-plate
apparatus and delays of 2, 4, 8, 16, 32, and 48 seconds.
Monkeys were given 0, 0.1, 0.3, or 1 mg/kg i.m. MDMA
in a within-subjects design 30 minutes before on-drug
test sessions. MDMA had no effect on overall accuracy
relative to saline at any of the doses tested. In contin-
uation of this study, Frederick et al. (1995b) tested the
same rhesus monkeys on the same task under different
MDMA treatments. Monkeys were given two daily injec-
tions of i.m. MDMA at an 8-hour interval for 14 consecu-
tive days. The dose of MDMA was increased every
2 weeks, such that doses of 0, 0.1, 0.3, 1, 3, 5.6, 10, and
20 mg/kg MDMA were each given for 14 consecutive
days in sequential order. On-drug testing took place
30 minutes after the first injection of each day, and
MDMA had no effect on overall accuracy relative to
saline at any dose. Five months later, monkeys were
given 0, 0.3, 1, 1.75, 3, or 5.6 mg/kg i.m. MDMA in a
within-subjects design 30 min before daily on-drug
test sessions. Doses of 0.3, 1, 1.75, and 3mg/kgMDMA
had no effect on overall accuracy relative to saline,
and the effect of 5.6 mg/kg MDMA could not be deter-
mined due to performance failure. In all, these studies
indicate that doses of 0.1, 0.3, 1, 1.75, 3, 5.6, 10, and
20mg/kgMDMAmay have no effect onworkingmemory.
LeSage et al. (1993) trained and tested adult White
Carneau pigeons on a DMS task using color illuminated
keys and delays of 0, 3, and 6 seconds. Pigeons were
given 0, 0.32, 1, 1.7, 3.2, 4.2, or 5.6 mg/kg i.m. MDMA in
a within-subjects design 10 minutes before on-drug test
sessions. Relative to saline, doses of 0.32, 1, and 1.7mg/kg
MDMAhadno effect on accuracy across all delays, doses of
3.2 and4.2mg/kgMDMAsignificantly decreasedaccuracy
across all delays, and a dose of 5.6 mg/kg MDMA com-
pletely suppressed responding. Ten days later, pigeons
were given i.m. MDMA at doses of 0 mg/kg for 2 days
(baseline), followed by 3.2 mg/kg for 20 days, 4.2 mg/kg
for 1 day (challenge dose), 3.2 mg/kg for 5 days, and
5.6 mg/kg for 1 day (challenge dose) (all consecutive
days). The final dose of 3.2 mg/kg MDMA and the
challenge doses of 4.2 and 5.6 mg/kg MDMA had no
effect on accuracy relative to saline (baseline) across all
delays. These findings suggest that doses of 3.2, 4.2, and
5.6 mg/kg MDMA initially impair performance on the
DMS task but these impairments diminish after treat-
ment with repeated doses ofMDMA.Nevertheless, doses
of 0.32, 1, 1.7, 3.2, 4.2, and 5.6 mg/kg MDMA appear to
have no effect on working memory.
Taffe et al. (2001) trained adult male rhesus monkeys
on a DNMS task using touchscreen stimuli. Monkeys
were first tested under delays of 0, 16, 32, and 64 seconds
for 4 weeks. The following week, monkeys were given
two daily injections of 10mg/kg i.m.MDMA at a 12-hour
interval for 4 consecutive days. Testing continued
during the MDMA treatment week (3–5 hours after
the first injection of each day, so testing occurred
after the peak drug effect) and for the 21 weeks following
treatment. During all three testing periods (pretreat-
mentweeks, treatment week, and posttreatment weeks),
MDMA-treated monkeys and saline controls did not
significantly differ in accuracy across all four delays.
The accuracy of MDMA-treated monkeys was signifi-
cantly reduced during the treatment week compared
with thepretreatmentweeksatdelays of 0and64 seconds,
but this effect can be attributed to performance deficits
rather than working memory deficits as the reductions
were seen at both no delay and a long delay. In all, these
findings indicate that treatment with repeated doses of
10 mg/kgMDMAmay have no effect on working memory
during treatment and for at least 5 months later.
Marston et al. (1999) trained and tested adult male
Lister Hooded rats on a DNMS task using retractable
levers and delays of 0.3, 1, 3, 5.6, 10, 17.6, and 30 seconds.
Rats were given two daily injections of i.p. MDMA at
a 10-hour interval for 3 consecutive days at doses of
10 mg/kg MDMA on day 1, 15 mg/kg MDMA on day 2,
and 20 mg/kg MDMA on day 3. Testing continued
during MDMA treatment (45–130 min after the first
injection of each day) and for the 3–16 days following
treatment. MDMA suppressed responding during the
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treatment days, so the results on accuracy were not
reported. During the posttreatment days, the accuracy
of MDMA-treated rats was significantly reduced rela-
tive to saline controls at the longer delays of 17.6 and
30 seconds (but not the shorter delays) during the last
few days of testing. These results suggest that treatment
with increasing doses of 10–20 mg/kg MDMA impairs
working memory for up to about 2 weeks later.
a. Odor span task. Hawkey et al. (2014) conducted a
variation of the DNMS task, the odor span task (OST),
and this study is included in Table 2. In the OST, the
stimuli are plastic cups that contain sand and a food
reinforcer with different scented lids. On the first trial, a
single olfactory stimulus is presented. On the second
trial, the familiar olfactory stimulus is presented with a
novel olfactory stimulus. On each subsequent trial, an
additional olfactory stimulus is added so that the number
of familiar olfactory stimuli increases with each trial, but
there is always only one novel olfactory stimulus. Beyond
the fifth trial, the number of stimuli does not increase, but
the familiar and novel scents are still changed between
trials. Simple discrimination trials are also interspersed
between OST trials, which test for simple task perfor-
mance but not working memory functioning. On each
simple discrimination trial, the same five olfactory stimuli
are presented and the single stimulus that is reinforced
remains constant for all trials (while responses to the
other four stimuli are never reinforced). In this study,
each test session consisted of 24 OST trials and 6 simple
discrimination trials. OST percent correct, simple discrim-
ination percent correct, span (number of trials completed
before an error), and longest run (longest series of correct
responses) were scored for each session.
Hawkey et al. (2015) trained adultmale Sprague-Dawley
rats on the OST and simple discrimination tasks to a
criterion level prior to testing. Rats were given 0, 0.3, 1,
1.8, or 3 mg/kg i.p. MDMA in a within-subjects design
15 minutes before on-drug test sessions. Doses of 0.3, 1,
and 1.8 mg/kg MDMA had no effect on OST percent
correct, simple discrimination percent correct, span,
or longest run relative to saline. A dose of 3mg/kgMDMA
significantly decreased span and longest run relative to
saline but had no effect on OST percent correct or simple
discrimination percent correct. The reductions in span
and longest run were due to a significant increase in
response omissions on both simple discrimination and
OST trials, rather than being due to working memory
deficits. Another group of rats was given two daily injec-
tions of 10 mg/kg i.p. MDMA for 4 consecutive days and
then tested off-drug 3 days later for a total of 10 sessions.
MDMA-treated rats and saline controls did not signif-
icantly differ in OST percent correct, simple discrimi-
nation percent correct, span, or longest run. In all,
these findings demonstrate that doses of 0.3, 1, 1.8,
and 3 mg/kg MDMA have no on-drug effect on working
memory (although 3 mg/kg MDMA did produce perfor-
mance deficits), and pretreatment with repeated doses
of 10 mg/kg MDMA also have no subsequent effect on
working memory.
2. Spontaneous and Delayed Alternation. The spon-
taneous alternation (SA) and delayed alternation (DA)
tasks (see Dudchenko, 2004; Hughes, 2004) are used to
assess spatial working memory in rodents, typically on
a T- or Y-maze. The main difference between these two
tasks is that SA responses are driven by the natural
tendency for rodents to explore novel environments, and
DA responses are driven by food reinforcement. In both
tasks, the goal of the animal is to investigate a new arm
of the T- or Y-maze rather than one that they recently
visited.
There are two main versions of the SA task, contin-
uous SA and two-trial SA. The continuous SA task
is completed in one trial, during which the animal is
allowed to freely explore all three arms of the maze for
the entire duration (usually several minutes). Number
of alternations, defined as consecutive entries into all
three arms without repeated entries, is scored for each
animal and converted to percent alternation (ratio of
actual to possible alternations given number of arm
entries). The two-trial SA task consists of a forced trial
and a test trial. On the forced trial, the animal is placed
at the end of the “start” arm and is only allowed to enter
one other arm (the “familiar” arm), as the third arm
(the “novel” arm) is blocked by a door. Normally, a delay
period is placed after the forced trial and before the test
trial. On the test trial, the animal is returned to the end
of the “start” armand allowed to enter either the “familiar”
arm or the “novel” arm (all three arms are open). A correct
response or alternation is defined as an entry into the
“novel” arm on the test trial.
The DA task is quite similar to the two-trial SA task.
Each session usually consists of one forced trial followed
by several choice trials. The forced trial is conducted in
the same manner as the SA task, except a food rein-
forcer is placed at the end of the “familiar” arm. On the
first choice trial, the food reinforcer is placed at the end
of the “novel” arm, and for all subsequent choice trials,
the food reinforcer is placed at the end of the arm that
was not entered on the previous trial. Only one entry is
permitted per trial, and a correct response or alterna-
tion is defined as a reinforced response, an entry into the
arm that was not entered on the previous trial.
Table 2 includes the seven studies that explored the
effects of MDMA on the SA (four studies) and DA (three
studies) tasks. Of these studies, only Costa et al. (2014)
conducted the continuous SA task. In this study, male
C57BL/6 mice were given two daily injections of 10 mg/kg
i.p. MDMA at a 4- to 6-hour interval on the 2nd and 5th
days of eachweek for 9weeks, which began in adolescence
and extended into adulthood. Mice were tested on a
Y-maze, off-drug, on the 7th day of drug treatment
weeks 1, 4, and 9 and postdrug treatment weeks 2 and 3.
The percent alternations of MDMA-treated mice and
saline controls did not significantly differ at any time
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point, suggesting that treatment with repeated doses
of 10 mg/kg MDMA has no effect on spatial working
memory for up to 3 weeks after treatment.
Edut et al. (2011) and Cassel et al. (2005) tested
rodents on the two-trial SA task at least 1 week after
MDMA treatment. Edut et al. gave adult male ICR
mice a single injection of 10 mg/kg i.p. MDMA and
tested them 7 and 30 days later on a Y-maze. Mice were
permitted to enter multiple arms during a 5-minute
forced trial and a 2-minute choice trial, which were
separated by a 2-minute delay period. The preference index
[(time at “novel” arm – time at “familiar” arm)/(time at
“novel” arm + time at “familiar” arm)] of MDMA-treated
mice and saline controls did not significantly differ at both
7 and 30 days later. Cassel et al. gave adult male Long
Evans rats a daily injection of 10 mg/kg i.p. MDMA for
4 consecutive days. Four days later, rats began testing on
a T-maze, and were tested once daily for 4 days and then
twice on a 5th day. Rats were permitted to enter only one
arm during each trial, which were separated by a
30-second delay period. The overall percent alternation
of MDMA-treated rats and saline controls did not signif-
icantly differ. These two studies suggest that pre-
treatment with a dose of 10 mg/kg MDMA, whether
administered once or repeatedly, has no subsequent
effect on spatial working memory.
Kolyaduke and Hughes (2013) performed a variation
of the two-trial SA task in which all three arms of a
Y-maze were open during both trials (now referred to as
the acquisition and retention trials). During the acqui-
sition trial, one arm contained a black insert and one
arm contained a white insert, and during the retention
trial, both arms contained a black insert (the changed
arm = the novel arm). Multiple choices were allowed
during the 6-minute acquisition trial and the 3-minute
retention trial, and there was no delay period between
the two trials. Male and female PVG/c hooded rats were
given a daily injection of 10 mg/kg i.p. MDMA for
10 consecutive days during early adolescence (postnatal
days 35–45) or late adolescence (postnatal days 45–55).
Rats were tested as adults on two separate days at least
35 days afterMDMA treatment (after postnatal day 90).
Both early and late adolescenceMDMA-treated rats did
not significantly differ from saline controls in percent
novel entries and percent time spent in the novel arm,
indicating that pretreatment with repeated doses of
10 mg/kg MDMA may have no subsequent effect on
spatial working memory.
Ricaurte et al. (1993) gave adult male Long Evans
rats two daily injections of 20 mg/kg s.c. MDMA at an
8-hour interval for 4 consecutive days, and this treat-
ment was repeated again about 1 week later. About
1 month later, rats began training for a DA task on a
T-maze. Seven weeks after MDMA treatment, rats
began daily test sessions consisting of one forced trial
followed by 10 choice trials under a constant delay of
5 seconds. The percent correct of MDMA-treated rats
and saline controls increased at a similar rate over the
20 test sessions, and there were no significant differ-
ences between groups. After 5 weeks of testing under a
constant delay, variable delays of 5, 30, 60, 120, and
180 seconds were introduced, and testing continued for
an additional 3 weeks. The percent correct of MDMA-
treated rats and saline controls decreased at a similar
rate as the duration of the delay period increased, and
again there were no significant differences between
groups. Findings from this study indicate that pre-
treatment with repeated doses of 20 mg/kg MDMAmay
have no subsequent effect on spatial working memory.
Young et al. (2005) performed a two-part task on a
double Y-maze: the first part was a spatial discrimina-
tion (SD) task (described in section V.C.3.a) and the
second part was a DA task (summarized here). Young
adult male Wistar rats were trained to criterion on
the task prior to being introduced to delays of 0, 15, or
60 second and then on-drug testing. Rats were injected
with 0, 1.25, 2.25, or 5 mg/kg i.p. MDMA in a within-
subjects design 20 minutes before on-drug test sessions.
Each test session consisted of one forced trial followed
by 24 choice trials with randomly allocated delays. Over-
all, the percent correct of all rats significantly decreased
as the duration of the delay increased. Relative to saline,
doses of 1.25 and 2.25 mg/kg MDMA had no effect
on percent correct at any delay, a dose of 2.25 mg/kg
MDMA produced a small increase in percent correct
under a 60-second delay, and a dose of 5 mg/kg MDMA
significantly decreased percent correct at all delays.
Typically, this deficit would be attributed to a perfor-
mance impairment, but since 5 mg/kg MDMA had no
effect on accuracy in the SD component, which required
the same performance abilities (see section V.C.3.a),
this may be due to a working memory impairment. In
all, these findings suggest that a dose of 1.25 or
2.25 mg/kg MDMA has no effect on spatial working
memory, but a dose of 5 mg/kg MDMA may produce
spatial working memory deficits.
Viñals et al. (2012) performed an operant/nonspatial
version of the DA task in which adult male C57BL/6
mice were trained to alternate nose-poking between two
nose-poking holes. Mice were trained to a criterion level
on the task, and then given two daily injections of 3 or
30 mg/kg i.p. MDMA at a 4-hour interval for 4 consec-
utive days. Mice were tested off-drug for 7 days after
MDMA treatment and introduced to delays of 2, 4, 6, or
8 seconds in a random order. Mice given 3mg/kgMDMA
injections and saline controls did not significantly differ
in percent correct over all 7 days of testing. The percent
correct of mice given 30 mg/kg MDMA injections was
significantly higher than saline controls on the 1st day
of testing but did not significantly differ from saline
controls for the remaining 6 days. The increased accu-
racy on the 1st day of testingmay be because of a slowed
reaction time rather than working memory enhance-
ments, as mice given 30 mg/kg MDMA injections also
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demonstrated a significantly longer response latency
compared with saline controls. In all, these results
suggest that pretreatment with repeated doses of 3 or
30mg/kgMDMAhas no subsequent effect on nonspatial
working memory.
3. Radial Arm Maze. The radial arm maze (RAM)
(see Dudchenko, 2004; Quillfeldt, 2016) is a useful tool
to study spatial working and reference memory in
rodents. The goal of this task is to learn and remember
the location of food pellets using spatial cues. Perfor-
mance can be separated by type of memory (working vs.
reference). The effects of MDMA on working memory in
theRAM taskwill be discussed here, while the effects on
reference memory will be reviewed in section V.C.2.
The RAM consists of a central hub that provides
access to eight radiating arms. All eight arms are
equal in length, and a food well is attached to the end
of each arm. The entire maze is typically elevated
above the floor in a room with many distal spatial
cues at fixed locations. Prior to training, each animal
is randomly assigned a set of four baited arms and four
nonbaited arms, which remains fixed for the remainder
of the experiment. Training is usually conducted daily
(or sometimes spaced by 1 to 2 days), with all animals
completing several trials per day (2–6 trials/day for the
studies reviewed). Before each trial, food pellets are
placed in the food wells of the four baited arms assigned
to that animal. The trial then begins by placing the
animal in the central hub facing arm number one. The
animal is typically allowed to enter four arms per trial
before being removed from the maze. The number of
working memory errors, defined as entries into a baited
arm that has already been visited in that same trial,
is scored for each trial. A single entry into each baited
arm reflects accurate spatial working memory of the
food pellet locations.
Table 2 includes the six studies that used the RAM to
evaluate the effects ofMDMAon spatial workingmemory.
Five of the studies used the general methods outlined
above, while Braida et al. (2002) used an alternative
procedure that is described below.
Hernandez-Rabaza et al. (2010) and Ros-Simó et al.
(2013) treated adolescent male rodents with two injec-
tions of MDMA on a single day. Hernandez-Rabaza
et al. gave Long Evans rats two injections of 10 mg/kg
i.p. MDMA at a 6-hour interval, 12 days prior to training.
MDMA-treated rats and saline controls exhibited a de-
crease in working memory errors over the 5 days of
training, and the number of working memory errors
did not significantly differ between groups. Ros-Simó
et al. began training CD1 mice prior to any MDMA
administration. Each animal was assigned only three
baited arms, and animals were not limited to a certain
number of armentrieswithin each trial.Micewere trained
for a total of 12 consecutive days and were given two
injections of 20 mg/kg i.p. MDMA on the 12th train-
ing day, one immediately after training and another
2 hours later. Three days later, mice were subject to an
additional training session, during which the number of
working memory errors produced by MDMA-treated
mice and saline controls did not significantly differ. The
findings of these two studies suggest that pretreatment
with two doses of 10 or 20 mg/kg MDMA has no later
effect on spatial working memory.
Figure 5 presents the findings of Kay et al. (2010),
which exemplify dose-dependent effects of MDMA on
working memory. Kay et al. trained adult male Sprague-
Dawley rats off-drug until all rats reached a criterion of
at least 75% correct arm entries for 7 days. After reaching
criterion, rats began on-drug training. Rats were given 0,
0.75, 3, or 4 mg/kg i.p. MDMA in a within-subjects design
15 minutes before each day of training. Relative to saline,
a dose of 0.75 mg/kg MDMA had no effect on the mean
overall percent correct, but doses of 3 and 4mg/kgMDMA
significantly decreased the mean overall percent correct
(Fig. 5A). The deficits produced by 3 mg/kg MDMA were
not due to working memory impairments, as this dose did
not significantly impact the percent of working memory
errors (number of errors/number of errors possible per
day). A dose of 4 mg/kg MDMA did significantly increase
the percent of working memory errors relative to saline;
however the percent of working memory errors was
still significantly smaller than the percent of reference
Fig. 5. Dose-dependent effects of MDMA on the radial arm maze task.
0.75 mg/kg MDMA had no effect on overall accuracy (A) or errors (B),
while 3 and 4 mg/kg MDMA impaired overall accuracy (A) and increased
working (4 mg/kg only) and reference memory errors (B). Data redrawn
with permission from Figs. 1 and 3 in Kay et al. (2010).
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memory errors (Fig. 5B). These findings indicate that
doses of 0.75 and 3 mg/kg MDMA have no effect on
spatial working memory, but a larger dose of 4 mg/kg
MDMA slightly impairs spatial working memory.
Kay et al. (2011) and Harper et al. (2013) conducted
similar experiments inwhich adultmale Sprague-Dawley
rats were treated with MDMA before and/or during
training. Kay et al. gave rats four injections of 10 mg/kg
i.p. MDMA at 2-hour intervals, 2 days prior to training.
Rats were trained off-drug until all animals reached
training criterion (28 days later). Over the 24 off-drug
training sessions, the average percent correct of MDMA-
treated rats increased at a slower rate than saline
controls. Two days after off-drug training, on-drug train-
ing began and continued for a total of 12 days. Rats were
given 0 or 4 mg/kg i.p. MDMA in a within-subjects design
20 minutes before each on-drug training session. MDMA
significantly decreased the average percent correct
relative to saline, but this impairment was signifi-
cantly smaller in rats treated withMDMA prior to off-
drug training relative to saline controls. Nonetheless,
the impairments observed during off- and on-drug train-
ing were not due to working memory deficits, as working
memory error percentage was not significantly affected
by any MDMA treatment.
Harper et al. also gave rats four injections of 10 mg/kg
i.p. MDMA at 2-hour intervals. Training began after
MDMA treatment and lasted for 47 days. Most training
sessions took place off-drug, except some rats were
given 4 mg/kg i.p. MDMA before training sessions
on days 8, 15, 22, 28, 34, and 41. The average percent
correct of rats pretreated withMDMAprior to all training
sessions was significantly lower than saline controls on
both off-drug and on-drug training days. MDMA also
significantly reduced average percent correct during
on-drug training days relative to saline. Again, none
of these impairments were due to working memory
deficits, as working memory error percentage was not
significantly affected by any MDMA treatment. The
findings of Kay et al. and Harper et al. suggest that
pretreatment with four doses of 10 mg/kg MDMA has
no subsequent effect on spatial working memory, and
a dose of 4 mg/kg MDMA also has no on-drug effect on
spatial working memory.
Braida et al. (2002) conducted an alternative working
memory task on the RAM. In this version, all eight arms
of the maze are baited, and the animal’s goal is to enter
all eight arms only one time during each trial. The
number of errors are scored for each trial, which is
synonymous with workingmemory errors on the typical
RAM task (i.e., re-entries into a baited arm). Here, the
task was conducted both without a delay and with a
2-hour delay between the fourth and fifth arm entry.
Adult male Wistar rats were trained on the task to a
criterion level, and then began on-drug training for
3 consecutive days. Rats were given a single injection
of 1, 2, or 3 mg/kg i.p. MDMA 20 minutes before each
on-drug training session. Without a delay, MDMA had
no effect on the total number of errors relative to saline.
With a 2-hour delay, doses of 1 and 2 mg/kg MDMA had
no effect on the total number of errors during the pre-
delay period (first 4 choices) and post-delay period (last
4 choices) relative to saline. A dose of 3 mg/kg MDMA
also had no effect on the total number of errors during
the pre-delay period, but significantly increased the total
number of errors during the post-delay period relative to
saline. These results suggest that doses of 1 and 2 mg/kg
MDMA have no effect on spatial working memory, but a
dose of 3mg/kgMDMA impairs spatial workingmemory.
4. Other Working Memory Tasks.
a. Morris water maze. The standard Morris water
maze (MWM) task (Morris, 1984) typically assesses spatial
learning and spatial referencememory (see section V.C.1);
however the task procedures can be manipulated to
measure spatial working memory (see Vorhees and
Williams, 2006). On the standardMWM task, the hidden
platform remains in the same location throughout
acquisition training, and therefore long-term memory
is required to navigate to the platform. On the working
memory version of the MWM task, the location of the
hidden platform is changed each day, and therefore
long-term memory of the platform location is not
required and rather the task demands working mem-
ory functioning. The two studies that examined the
effects of MDMA on the working memory MWM task
are included in Table 2. The methods for these studies
are briefly discussed here, but see section V.C.1 for a
full description of the MWM apparatus/methods.
Robinson et al. (1993) conducted a spatial navigation
task on the MWM that consisted of three parts: an
initial learning set, a retention test (reviewed in section
V.C.1.a), and a second learning set. The learning sets
assessed working memory and were each 3 consecutive
days in total. On each day, the platform location was
chosen randomly, which remained constant for that day
only. Eight trials were performed per day, with two
trials from each of the four starting locations. Adult
male Sprague-Dawley rats were given two daily injec-
tions of 10 mg/kg i.p. MDMA at a 12-hour interval for
4 consecutive days. The initial learning set began 2 days
after MDMA treatment, and the second learning set
began 8 days after MDMA treatment. On the initial
learning set, the escape latency of MDMA-treated rats
was significantly higher than saline controls on the first
few trials of each day, but both groups demonstrated a
significant decrease in escape latency across trials and
showed no significant differences by the last few trials.
On the second learning set, both MDMA-treated rats
and saline controls demonstrated a significant decrease
in escape latency across trials, and there were no
significant differences between groups. These results
suggest that pretreatment with repeated doses of
10 mg/kg MDMA has no subsequent effect on spatial
working memory.
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Galizio et al. (2014) performed a repeated acquisi-
tion/performance procedure on the MWM. The acqui-
sition component assessed working memory, as the
platform location changed each day, while the perfor-
mance component (see section V.C.1.a) assessed refer-
ence memory, as the platform location remained fixed
over all days. Each day consisted of 12 trials that
alternated between acquisition and performance trials.
Adult male Sprague-Dawley rats were trained on the
task prior to on-drug testing. Rats were given of 0, 0.3,
1.0, 1.7, 3.0, or 5.6mg/kg i.p.MDMA in awithin-subjects
design 15 minutes before each on-drug test session.
On the acquisition component, doses of 0.3, 1.0, and
1.7 mg/kg MDMA had no effect on escape latency, while
doses of 3.0 and 5.6 mg/kg MDMA significantly in-
creased escape latency relative to saline. Doses of 3.0
and 5.6 mg/kg MDMA also produced significant in-
creases in latency on the performance component (see
section V.C.1.a), and therefore these deficits can be
attributed to performance impairments rather than
working memory impairments. In all, these results
reveal that doses of 0.3, 1.0, 1.7, 3.0, and 5.6 mg/kg
may have no effect on spatial working memory.
C. Spatial Learning and Memory
1. Morris Water Maze. The Morris water maze
(MWM) (Morris, 1984) is one of the most widely used
tasks for studying spatial learning and memory in
rodents. The objective of this task is to learn to navigate
to a hidden platform in a large circular pool of water
using spatial cues. The pool is arbitrarily divided into
four quadrants and is in a room with many distal visual
cues at fixed locations (e.g., furniture, wall art, etc.). There
are two main stages of the task: acquisition training and
the probe test, which assess spatial learning and spatial
reference memory, respectively.
Acquisition training takes place over a few consecu-
tive days (3–5 days for the studies reviewed), with all
animals completing several trials per day (3–8 trials/
day for the studies reviewed). On each trial, an animal is
placed into the water facing the wall of the pool and is
expected to swim and escape onto the hidden platform.
The hidden platform remains in the same location
throughout acquisition training, but the starting loca-
tion of the animal is varied between trials. As a result,
spatial memory of the distal visual cues is required to
identify the location of the hidden platform. The escape
latency (i.e., time taken to reach the platform), and often
the path length (i.e., distance swam to reach the
platform), is recorded for all trials. A significant
decrease in escape latency/path length over days of
acquisition training suggests spatial learning of the
platform location.
The probe test takes place after the last acquisition
training session, either the same day or the following
day. The procedure is similar to acquisition training,
except the hidden platform is removed from the pool and
each animal performs only one trial. The total time
spent swimming in each quadrant of the pool, or some-
times the average distance from the platform location, is
recorded. A significantly greater amount of time spent
swimming in the target quadrant (i.e., quadrant where
the hidden platform used to be located) relative to the
other three quadrants indicates spatial referencememory
of the platform location.
Table 3 presents the 14 studies that report the effects
of MDMA on the standard MWM task. Most of these
studies completed both acquisition training and the
probe test. Some studies do not report the change in
escape latency/path length over days of acquisition
training, and a few other studies do not report findings
on the probe test. In these particular studies, effects on
spatial learning or spatial reference memory (respec-
tively) cannot be properly assessed. All 14 studies used
high doses of 5–20 mg/kg MDMA, and none used lower,
typical doses of less than 3 mg/kg MDMA.
Taghizadeh et al. (2016) were the only group to
conduct on-drug acquisition training. Adult male Wistar
rats were given 5, 10, or 15mg/kg i.p. MDMA 30minutes
before the first trial of acquisition training on all 4 days.
During the probe test on the following day (off-drug),
MDMA-treated rats spent significantly less time in the
target quadrant than saline controls. These results
suggest that doses of 5, 10, and 15 mg/kg MDMA
impair spatial reference memory when acquisition
occurs on-drug.
The remaining studies explored the effects of admin-
istering MDMA one or more days prior to acquisition
training. Mirzaei et al. (2013) gave adult male Wistar
rats a single injection of 10 mg/kg i.p. MDMA, 3 days
prior to acquisition training. The escape latency and
path length of MDMA-treated rats were significantly
higher than that of saline controls on the 1st day of
training, but these values decreased significantly over
the 2nd and 3rd day to a level comparable to that of the
saline controls. This suggests that pretreatment with a
dose of 10 mg/kg MDMA has no subsequent effect on
spatial learning.
Sprague et al. (2003), Cohen et al. (2005), Able et al.
(2006), Skelton et al. (2008), and Cunningham et al.
(2009) all gave adult male Sprague-Dawley rats multi-
ple injections of MDMA on a single day prior to
acquisition training. Sprague et al. gave rats two
injections of 20 mg/kg s.c. MDMA at a 12-hour interval,
1 week prior to acquisition training. The escape latency
and path length of MDMA-treated rats decreased
significantly over 3 days of acquisition training, and
there were no significant differences between MDMA-
treated rats and saline controls during acquisition.
During the probe test directly after the last acquisition
session, MDMA-treated rats spent significantly less
time in the target quadrant than saline controls, yet
significantly more time in the target quadrant than two
of the other three quadrants. Similarly, Cunningham
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et al. gave rats four injections of 7.5 mg/kg i.p. MDMA at
2-hour intervals, 24 days prior to acquisition training.
There were no significant differences between MDMA-
treated rats and saline controls in the decrease in
escape latency and path length over 5 days of acquisi-
tion training. During the probe test directly after
the last acquisition session, MDMA-treated rats spent
the same amount of time in all four quadrants,
unlike the saline controls that spent significantly more
time in the target quadrant than the other three
quadrants. Able et al. gave rats four injections of
15 mg/kg s.c. MDMA at 2-hour intervals, 12 days prior
to acquisition training. Again, there were no significant
differences between MDMA-treated rats and saline
controls during acquisition training, as both groups
exhibited similar decreases in escape latency over all
5 days. During the probe test on the following day, the
average distance from the platform location of MDMA-
treated rats was significantly greater than that of saline
controls. Cohen et al. also gave rats four injections of
15 mg/kg s.c. MDMA at 2-hour intervals, but at least
2 weeks prior to 5 days of acquisition training. On the
probe test the day after the last acquisition session,
there were no significant differences between MDMA-
treated rats and saline controls in percent time spent in
the target quadrant. Skelton et al. also gave rats four
injections of 15 mg/kg s.c. MDMA at 2-hour intervals,
14 days prior to acquisition training. The latency of
MDMA-treated rats and saline controls decreased in a
similar manner over 5 days of acquisition training.
During the probe test on the following day, the average
distance from the platform location of MDMA-treated
rats and saline controls did not significantly differ.
The findings from the five studies above suggest that
pretreatment with two doses of 20 mg/kgMDMA or four
doses of 7.5 or 15 mg/kg MDMA has no later effect on
spatial learning. The results from the probe test of these
studies suggest that pretreatment with two doses of
20 mg/kg MDMA or four doses of 7.5 mg/kg MDMA
subsequently impairs spatial reference memory, while
pretreatment with four doses of 15mg/kgMDMAhas no
later effect on spatial reference memory (apart from
Able et al.’s findings that this dose produces spatial
reference memory impairments).
The remainder of the studies investigated the conse-
quences of administering multiple daily injections of
MDMA on multiple days prior to acquisition training.
Camarasa et al. (2008) and Abad et al. (2014) treated
ratswith two daily injections ofMDMA for 4 consecutive
days. Camarasa et al. gave adult male Long Evans rats
two daily injections of 15 mg/kg s.c. MDMA at a 7-hour
interval for 4 consecutive days, 9 days prior to acquisi-
tion training. Unlike saline controls, the escape latency
of MDMA-treated rats did not significantly decrease
over 4 days of acquisition training. On the probe test the
following day, MDMA-treated rats also did not spend
significantlymore time in the target quadrant than that
predicted by random (1/4th of the total time). Abad et al.
gave adolescent male Sprague-Dawley rats two daily
injections of 20mg/kg s.c. MDMA for 4 consecutive days,
1 week prior to acquisition training. The escape latency
of MDMA-treated rats decreased at a faster rate than
saline controls over 4 days of acquisition training.
MDMA-treated rats and saline controls spent signifi-
cantly more time in the target quadrant than the
opposite quadrant on the probe test the next day. These
two studies have opposing findings. The results of
Camarasa et al. suggest that pretreatment with re-
peated doses of 15 mg/kg MDMA later impairs both
spatial learning and spatial reference memory, while
the results of Abad et al. suggest that pretreatmentwith
repeated doses of 20 mg/kg MDMA later enhances
spatial learning and has no effect on spatial reference
memory. The use of different rat strains or ages
(Camarasa et al. tested adult Long Evan rats and Abad
et al. tested adolescent Sprague-Dawley rats) may
account for this discrepancy in findings.
Busceti et al. (2008) used a similarMDMA regimen as
Camarasa et al. and Abad et al., but instead gave adult
male C57BL/6 mice two daily injections of 5 or 15 mg/kg
i.p. MDMA at a 2-hour interval for 6 consecutive days.
Acquisition training began 7 or 40 days after MDMA
treatment, and at both time points, the escape latency of
MDMA-treated mice did not significantly decrease over
the 4 days. On the probe test, mice given 5 mg/kg
MDMA injections spent significantly less percent time
than saline controls in the target quadrant when tested
7 days later but not when tested 40 days later. Mice
given 15 mg/kg MDMA injections spent significantly
less percent time than saline controls in the target
quadrant when tested 7 or 40 days later. These results
suggest that pretreatment with repeated doses of 5 or
15 mg/kg MDMA subsequently results in spatial learn-
ing and spatial reference memory deficits, but spatial
reference memory may return to normal by 40 days
after treatment with repeated doses of 5 mg/kg MDMA
only.
The next group of studies treated adult rats with
MDMA for 7 consecutive days. Kermanian et al. (2012)
gave adult male Sprague-Dawley rats a daily injection
of 10 or 20 mg/kg i.p. MDMA for 1 week. Acquisition
training began 1 week later, and unlike saline controls,
the escape latency of MDMA-treated rats did not
significantly decrease over the 4 days. Soleimani Asl
et al. (2015) gave male and female adult Sprague-
Dawley rats two daily injections of 5 mg/kg i.p. MDMA
for 1 week. On the following probe test, MDMA-treated
rats spent significantly less percent time in the target
quadrant than saline controls. Soleimani Asl et al.
(2011) and Soleimani Asl et al. (2013) gave adult male
Sprague-Dawley rats two daily injections of 5, 10, or
20 mg/kg i.p. MDMA at an 8-hour interval for 1 week.
Soleimani Asl et al. (2011) began 3 days of acquisition
training 1 week after MDMA treatment. The probe test
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took place the day after acquisition training, during
whichMDMA-treated rats and saline controls spent the
same percent time in the target quadrant. Soleimani
Asl et al. (2013) began 3 days of acquisition training the
day after MDMA treatment. The probe test also took
place the day after acquisition training, but MDMA-
treated rats spent significantly less percent time in the
target quadrant than saline controls. In addition to
testing the effects of a single dose of MDMA (described
above), Mirzaei et al. (2013) gave another group of adult
male Wistar rats two daily injections of 10 mg/kg i.p.
MDMA for 1 week and began acquisition training the
following day. The escape latency and path length of
MDMA-treated rats were significantly higher than that
of saline controls on the 1st day of training, but these
values decreased significantly over the 2nd and 3rd day
to a level comparable to that of saline controls.
The findings from the above studies are mixed. The
results of Kermanian et al. suggest that pretreatment
with repeated doses of 10 or 20 mg/kg MDMA leads to
spatial learning deficits, while the results of Mirzaei
et al. suggest that pretreatment with repeated doses
of 10 mg/kg MDMA has no effect on spatial learning.
Likewise, the results of Soleimani Asl et al. (2013, 2015)
suggest that pretreatment with repeated doses of 5, 10,
or 20 mg/kg MDMA leads to spatial reference memory
deficits. The results of Soleimani Asl et al. (2011),
however, suggest that pretreatment with repeated
doses of 5, 10, or 20 mg/kg MDMA has no effect on
spatial reference memory. These differences in findings
could be due to the timing of training/testing relative
to MDMA treatment. Soleimani Asl et al. (2013) and
Mirzaei et al. began acquisition training 1 day after
MDMA treatment and found learning and memory
deficits, while Soleimani Asl et al. (2011) and
Kermanian et al. (2012) began acquisition training
1 week after MDMA treatment and found no effects.
The differences between the findings of Kermanian
et al. and Mirzaei et al. could also be due to the use
of different rat strains (Sprague-Dawley vs. Wistar).
In all, it appears that pretreatment with MDMA for
7 consecutive days may produce spatial learning and
memory deficits within the week after treatment, but
not after 1 week.
Skelton et al. (2008), in addition to studying the
effects of multiple MDMA injections on a single day
(above), gave another group of animals the same
treatment weekly. Adult male Sprague-Dawley rats
were given four daily injections of 15 mg/kg s.c. MDMA
at 2-hour intervals once weekly for 5 weeks. Acquisition
training began 14 days later, during which the latency
of MDMA-treated rats and saline controls decreased
in a similar manner over all 5 days. During the probe
test on the following day, the average distance from
the platform location of MDMA-treated rats and saline
controls did not significantly differ. These results
suggest that pretreatment with repeated doses of
15 mg/kg MDMA has no subsequent effect on spatial
learning or spatial reference memory.
a. Morris water maze variations. Four studies in-
cluded in Table 3 used variations of the water maze to
assess the effects of MDMA on spatial learning and
memory. Robinson et al. (1993) conducted a spatial
navigation task that is similar to the standard MWM
task. Adult male Sprague-Dawley rats were given two
daily injections of 10 mg/kg i.p. MDMA at a 12-hour
interval for 4 consecutive days, 2 days prior to training.
The location of the hidden platform changed each day
of training, and therefore this phase measured work-
ing memory rather than spatial learning (see section
V.B.4.a). Training lasted for 3 days, and on the 4th day
the hidden platform was left in the same location as the
previous day for a retention test of spatial reference
memory of the platform location (similar to the probe
test in the standard MWM task). The escape latencies
of MDMA-treated rats and saline controls showed no
significant differences over all four trials of the reten-
tion test, which suggests that pretreatment with re-
peated doses of 10 mg/kg MDMA has no subsequent
effect on spatial reference memory.
Figure 6 portrays the findings of Galizio et al. (2014),
which exemplify dose-dependent effects of MDMA on
spatial learning and memory. Galizio et al. conducted
a repeated acquisition/performance procedure on the
MWM. Adult male Sprague-Dawley rats were trained
on the acquisition and performance components of the
task prior to any MDMA administration. Each training
day consisted of 12 trials that alternated between
acquisition and performance trials. The acquisition
component (see section V.B.4.a) assessed working mem-
ory, as the platform location changed each training day
but remained fixed for all trials on a particular day. The
performance component corresponded to acquisition
training on the standardMWM, as the platform location
remained fixed over all days of training. Once rats
reached criterion on training, the same procedure was
repeated on-drug. Unlike the other MWM studies,
MDMA was tested across a wide range of doses. Rats
were given 0, 0.3, 1.0, 1.7, 3.0, or 5.6mg/kg i.p.MDMA in
awithin-subjects design 15minutes before each on-drug
session. On the performance component, doses of 0.3,
1.0, and 1.7 mg/kg MDMA had no effect on escape
latency while doses of 3.0 and 5.6 mg/kg MDMA
significantly increased escape latency relative to saline.
These results suggest that doses of 0.3, 1.0, and
1.7 mg/kg MDMA have no effect on spatial learning
but doses of 3.0 and 5.6 mg/kg MDMA impair spatial
learning.
Compton et al. (2011) used a constant-start train-
ing and novel-start testing procedure on the MWM.
Adolescent male Long Evans rats were given a daily
injection of 10 mg/kg i.p. MDMA for 6 alternating days.
Rats were trained and tested as adults about 3 months
later. The experiment started with constant-start
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training, during which the starting location of each
rat and the platform location were invariable. Novel-
start testing began after rats reached training criterion,
which is executed in the same manner as acquisition
training on the standard MWM (variable starting
locations and a fixed platform location). Rats were
tested for 3 days, with each day consisting of six trials,
trials one, two, four, and five were constant-start trials
and trials three and six were novel-start trials. The
escape latency of MDMA-treated rats on novel-start
trials were significantly greater than that of saline
controls, suggesting that pretreatment with repeated
doses of 10 mg/kg MDMA during adolescence will
impair spatial learning as adults.
Edut et al. (2011) tested the effects of MDMA
treatment on the dry maze test, a variation of the
MWM that does not require swimming. The dry maze
consists of a circular arena with 20 tiny wells arranged
in a circular manner. The goal of the task is to learn the
location of the single well that is filled with water. Adult
male ICR mice were first trained to drink from all
20 wells, and then introduced to a procedure identical to
acquisition training on the standard MWM to learn the
water well location. Mice were given a single injection of
10 mg/kg i.p. MDMA and tested 7 and 30 days later.
Seven days afterMDMA treatment, the latency to reach
the water well of MDMA-treated mice and saline
controls decreased in a similarmanner over all 7 days of
testing. Thirty days afterMDMA treatment, the latency
of MDMA-treated mice was significantly higher than
saline controls on days 4 and 6 of acquisition, but both
groups showed significant decreases in latency over all
7 days and by the last day of acquisition there were no
significant differences. These results suggest that pre-
treatment with a dose of 10 mg/kg MDMA has no
subsequent effect on spatial learning.
2. Radial Arm Maze. As described in section V.B.3,
the radial arm maze (RAM) (see Dudchenko, 2004;
Quillfeldt, 2016) is a useful tool to study spatial working
and reference memory in rodents. Here, we review the
five studies that examined the effects of MDMA on
spatial reference memory using the RAM task, which
are outlined in Table 3. The methods for these studies
are as previously explained; however, now the outcome
variable of interest is the number of reference memory
errors per trial. Reference memory errors are defined
as entries into a nonbaited arm. Entries into only baited
arms reflect accurate spatial reference memory of the
food pellet locations.
Hernandez-Rabaza et al. (2010) gave adolescent male
Long Evans rats two injections of 10 mg/kg i.p. MDMA
at a 6-hour interval, 12 days prior to training. MDMA-
treated rats and saline controls exhibited a similar
decrease in reference memory errors over 5 days of
training. The total reference memory errors during all
5 days also did not significantly differ between groups.
Similarly, Ros-Simó et al. (2013) gave adolescent male
CD1 mice two injections of 20 mg/kg i.p. MDMA, but on
the 12th and last day of training (using the alternative
methods described in section V.B.3). One injection was
given immediately after training and the second was
given 2 hours later. Three days later, mice were subject
to an additional training session, during which MDMA-
treated mice produced significantly more reference
memory errors than saline controls. Although these
two studies administered similar MDMA treatments,
the findings of Hernandez-Rabaza et al. suggest that
pretreatment with a two doses of 10 mg/kg MDMA has
no later effect on spatial reference memory, while the
findings of Ros-Simó et al. suggest that treatment with
two doses of 20 mg/kg MDMA impairs consolidation of
spatial reference memory.
Kay et al. (2010) gave adult male Sprague-Dawley
rats (that were pretrained on the task) 0, 0.75, 3, or
4mg/kg i.p.MDMA inawithin-subjects design 15minutes
before each day of training. As summarized previously,
a dose of 0.75 mg/kg MDMA had no effect on the mean
overall percent correct, but doses of 3 and 4mg/kgMDMA
significantly decreased the mean overall percent correct
relative to saline. The deficits produced by doses of 3 and
4 mg/kg MDMA are primarily attributed to reference
memory impairments, as both doses significantly in-
creased the percent of reference memory errors relative
to saline, and the percent of referencememory errorswere
significantly higher than the percent of working memory
errors. As illustrated in Fig. 5, these findings indicate that
a dose of 0.75 mg/kg MDMA has no effect on spatial
reference memory but doses of 3 and 4 mg/kg MDMA
impair spatial reference memory.
Kay et al. (2011) and Harper et al. (2013) gave adult
male Sprague-Dawley rats MDMA before and/or during
training. Kay et al. gave rats four injections of 10 mg/kg
i.p. MDMA at 2-hour intervals, 2 days prior to off-drug
training. After 28 days of off-drug training, on-drug
training began and continued for a total of 12 days. Rats
were given 0 or 4 mg/kg i.p. MDMA in a within-subjects
Fig. 6. Dose-dependent effects of MDMA on a variation of the Morris
water maze task. 0.3, 1.0, 1.7 mg/kg MDMA had no effect on working
memory (acquisition) or spatial learning (performance), while 3 mg/kg
MDMA impaired spatial learning (performance). Data redrawn with
permission from Fig. 4 (middle) in Galizio et al. (2014).
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design 20 minutes before each on-drug training session.
The effects of MDMA on average percent correct that
were previously reported in section V.B.3 can be
attributed to reference memory deficits, as the effects
on average percent correct and reference memory error
percentage follow the same pattern. During off-drug
training, the reference memory error percentage of
MDMA-treated rats decreased at a slower rate than
saline controls. During on-drug training, MDMA signif-
icantly decreased the reference memory error percent-
age relative to saline (this impairment was also
significantly smaller in rats treated with MDMA prior
to off-drug training vs. saline controls).
Harper et al. (2013) gave rats four injections of
10 mg/kg i.p. MDMA at 2-hour intervals and began
training after MDMA treatment. Training lasted for
47 days, with a mix of on-drug sessions (days 8, 15, 22,
28, 34, and 41) and off-drug sessions (all other days).
Before the on-drug training sessions, some rats were
given 4 mg/kg i.p. MDMA. Again, the effects of MDMA
on average percent correct that were previously re-
ported in section V.B.3 can be attributed to reference
memory deficits, as the effects on average percent
correct and reference memory error percentage follow
the same pattern. The reference memory error percent-
age of rats pretreated with MDMA prior to all training
sessions was significantly higher than saline controls on
both off-drug and on-drug training days. MDMA also
significantly increased reference memory error percent-
age during on-drug training days relative to saline. The
findings of Kay et al. and Harper et al. suggest that
pretreatment with four doses of 10 mg/kg MDMA
subsequently impairs spatial reference memory, and a
dose of 4 mg/kg MDMA also impairs spatial reference
memory when on-drug.
3. Other Spatial Tasks.
a. Spatial discrimination. Young et al. (2005) used a
double Y-maze for a two-part task, spatial discrimina-
tion (SD) task, which assesses spatial reference memory
and is outlined in Table 3, and a delayed alternation
task, which assesses working memory and is described
in section V.B.2. The double Y-maze consists of four end
arms connected to a central stem (2 arms on each side of
stem). Every arm is virtually identical from inside the
maze, but the entire maze is in a room with many distal
visual cues. On every trial, the animal is placed on the
end of one of the arms on the left side of the maze, and
the goal is to navigate to a food reward that is on one of
the arms on the right side of the maze. The first part
of the task is the SD task, as the animal is faced with
the decision to turn left or right—one way leading to the
adjacent arm and the other leading to the central stem
and ultimately the food reward. Both options appear
identical to the animal because there is a door placed in
the central stembefore the arms on the right side. The task
therefore requires spatial referencememory of the location
of the central stem relative to the distal visual cues.
For this study, young adult male Wistar mice were
trained on the task above prior to any MDMA treatment.
After reaching training criterion, mice were introduced to
intertrial delays of 15 and 60 seconds and then tested
on-drugwith the same procedure.Micewere given 0, 1.25,
2.25, or 5 mg/kg i.p. MDMA in a within-subjects design
20 minute before each test session. MDMA had no effect
on percent correct choices at any delay relative to saline.
These findings demonstrate that doses of 1.25, 2.25, and
5mg/kgMDMAdonot influence spatial referencememory
retrieval.
D. Nonspatial Learning and Memory
1. Novel Object Recognition. The novel object recog-
nition (NOR) task (Ennaceur and Delacour, 1988) is a
relatively simple test of nonspatial memory. This
method is based on the natural tendency for rodents to
explore a novel object more than a familiar object.
Animals are first habituated to the testing environ-
ment, a box or circular arena that is typically under dim
lighting, on 1 or more days prior to testing. Testing
consists of two trials, a training trial and a test trial,
separated by a delay ranging from 1minute to 24 hours.
This task can measure short-termmemory or long-term
memory, depending on the duration of the delay. Short-
term memory does not require protein synthesis but
long-term memory does require protein synthesis, and
the transition from protein synthesis-independent to
protein synthesis-dependent long-term potentiation
begins about 2 hours after memory acquisition (Frey
and Morris, 1997; Lu et al., 2008). Therefore, we can
consider that delays of less than 2 hours measure
short-term recognition memory, and delays of 2 hours
or more measure long-term recognition memory.
During the training trial, the animal is presented
with two identical objects (“A”), and the total time spent
exploring the two objects is measured. During the test
trial (following the delay), the animal is presented with
one familiar object (“A”) and one novel object (“B”), and
the time spent exploring each object ismeasured. Object
exploration is defined as touching, sniffing, or directing
the nose and vibrissae toward the object at a distance of
less than 1 to 2 cm. Significantly more exploration of the
novel object B than of the familiar object A in the test
trial is an indicator of object recognition memory. A
“discrimination index” or “discrimination ratio” is usu-
ally calculated to capture this data. The “discrimination
index” is the difference in exploration times of the novel
object B and the familiar object A, divided by the total
exploration time of the two objects in the test trial. The
discrimination ratio is the exploration time of the novel
object B divided by the total exploration time of the two
objects in the test trial. A higher discrimination index or
discrimination ratio reflects greater memory retention
of the familiar object.
Table 4 outlines the 22 studies that investigated the
effects of MDMA on the NOR task. Similar to the MWM
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studies, most of the NOR studies used high doses of 3–
20 mg/kg MDMA, and none used lower, typical doses of
less than 3mg/kgMDMA. For most of these studies, the
rodents were pretreated with MDMA and then trained
and tested on the task at a later time point. Two of the
22 studies (Ros-Simó et al., 2013; Shortall et al., 2013),
however, administered MDMA on the same day as the
training and/or test trials, and these studies will be
discussed first.
Instead of conducting only one training trial, Ros-Simó
et al. (2013) trained adolescent male CD1 mice daily for
3 days. Mice were given two injections of 20 mg/kg i.p.
MDMA, one directly after the third training trial and
another 2 hours later. The test trial took place 72 hours
later. The discrimination index of MDMA-treated mice
was significantly less than that of saline controls. These
results suggest that two doses of 20 mg/kg MDMA
administered after memory acquisition leads to impair-
ments in long-term recognition memory. Shortall et al.
(2013) gave young adult male Lister Hooded rats a daily
injection of 10 mg/kg i.p. MDMA for 2 consecutive days.
The training trial began 30 minutes after the drug
injection on the 2nd day, which was followed by a
2-hour delay and then the test trial. Rats treated with
MDMA did not explore the novel object more than the
familiar object, and the discrimination ratio of MDMA-
treated rats was significantly less than that of saline
controls. This suggests that a dose of 10 mg/kg MDMA
impairs long-term recognition memory when admin-
istered on the day before and the day of memory
acquisition/retrieval. The findings of Ros-Simó et al.
and Shortall et al. together suggest thatMDMA impairs
long-term recognitionmemory when on-drug during the
memory consolidation phase.
Nawata et al. (2010) and Edut et al. (2011) gave adult
male CD1 and ICR (respectively) mice a single injection
of 10 mg/kg i.p. MDMA. Nawata et al. ran the training
and test trials 1 or 7 days afterMDMA treatment, with a
3-hour delay between trials. The discrimination indexes
of MDMA-treated mice and saline controls were com-
parable at both 1 and 7 days posttreatment. Edut et al.
ran the training and test trials 7 or 30 days afterMDMA
treatment, with a 24-hour delay between trials. The
discrimination indexes of MDMA-treated mice and
saline controls were comparable at 7 days posttreat-
ment, but MDMA-treated mice showed significant
reductions relative to saline controls at 30 days
posttreatment. Together, these findings suggest that
pretreatment with a dose of 10 mg/kg MDMA has no
effect on long-term recognition memory up to 1 week
after treatment, but deficits may arise 30 days after
treatment.
The following group of studies treated rats with
multiple injections of MDMA on a single day prior to
testing. Figure 7 depicts the findings of Rodsiri et al.
(2011), which exemplify dose-dependent effects of
MDMA on nonspatial learning and memory. Rodsiri
et al. gave adult male Lister Hooded rats three injec-
tions of 3 or 6mg/kg i.p.MDMAat 2-hour intervals. Rats
were tested 2 weeks later, with a 2-hour delay between
trials. Rats given 3 mg/kg MDMA injections and saline
controls did not exhibit differences in discrimination
ratios, but the discrimination ratio of rats given 6mg/kg
MDMA injections was significantly less than that
of saline controls (Fig. 7B). These findings indicate that
there may be dose-dependent effects of MDMA on long-
term recognition memory, as pretreatment with three
doses of MDMA had no later effect at 3 mg/kg MDMA
but led to memory impairments at 6 mg/kg.
In a similar study, Piper et al. (2008) gave young
adult male Sprague-Dawley rats four injections of
10 mg/kg s.c. MDMA at 1-hour intervals. Rats were
tested at 15–17 and 17–19 days after MDMA treatment
with shorter 15- and 60-minute delays, respectively.
The discrimination ratios of MDMA-treated rats and
saline controls did not significantly differ during either
test. Cohen et al. (2005), Able et al. (2006), and Skelton
et al. (2008) all gave adult male Sprague-Dawley rats
four injections of 15 mg/kg s.c. MDMA at 2-hour
intervals. Able et al. tested their rats 30 days after
MDMA treatment and Cohen et al. and Skelton et al.
tested their rats at least 5 weeks after MDMA treat-
ment. All three studies used a 1-hour delay period and
found that during the test trial MDMA-treated rats and
saline controls explored the novel object more than the
familiar object, and both groups explored the novel
object for a similar amount of time. The findings from
the above studies suggest that pretreatment with four
doses of 10 or 15 mg/kgMDMA has no subsequent effect
on short-term recognition memory.
The remaining studies treated animals with MDMA
over several days prior to testing. Morley et al. (2001)
and McGregor et al. (2003) treated adult male Wistar
rats with MDMA for 2 consecutive days. Morley et al.
gave rats one or four (at 1-hour intervals) daily injec-
tions of 5 mg/kg i.p. MDMA for 2 consecutive days. Rats
were trained and tested 14 weeks later with a
15-minute delay and again 1 more week later with a
60-minute delay. The discrimination ratio of rats given
one daily injection did not significantly differ from that
of saline controls at either delay. The discrimination
ratio of rats given four daily injections did not signifi-
cantly differ from that of saline controls at the
60-minute delay, but was significantly less than saline
controls at the 15-minute delay. McGregor et al. also
gave rats four daily injections of 5 mg/kg i.p. MDMA at
1-hour intervals for 2 consecutive days. Approximately
10–12 weeks later, rats were tested with a 1-hour delay
between trials. Two “preliminary” days of testing were
conducted followed by a third identical day of testing
that provided the reported data. The discrimination
ratio of MDMA-treated rats was significantly less than
that of saline controls. In all, the findings from these two
studies suggest that treatment with one dose of 5 mg/kg
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MDMA for 2 consecutive days has no subsequent effect
on short-term recognition memory, while treatment
with four doses of 5 mg/kg MDMA for 2 consecutive
days may impair short-term recognition memory (with
the exception ofMorley et al.’s findings at the 60-minute
delay).
Abad et al. (2014) gave adolescent male Sprague-
Dawley rats two daily injections of 20 mg/kg s.c. MDMA
for 4 consecutive days. Rats were tested 1 week later
with a 1-hour delay between trials. MDMA-treated rats
and saline controls explored the novel object for signif-
icantly more percent of the total exploration time than
the familiar object. These findings indicate that pre-
treatment with repeated doses of 20mg/kgMDMAmay
have no subsequent effect on short-term recognition
memory.
In addition to testing a single dose of MDMA, Nawata
et al. (2010) gave another group of adult male CD1 mice
a daily injection of 10 mg/kg i.p. MDMA for 1 week.
These mice were also tested 1 or 7 days later with a
3-hour delay between trials. The discrimination index of
MDMA-treated mice was significantly less than that
of saline controls at 1 and 7 days posttreatment;
however this value was significantly above chance at
1 day posttreatment. Although this study found that
pretreatment with a single dose of 10mg/kgMDMAhad
no effect on long-term recognition memory (see above),
these additional findings suggest that pretreatment
with repeated doses of 10 mg/kg MDMA may lead to
long-term recognition memory deficits, with more pro-
nounced deficits 1 week after treatment versus 1 day.
van Nieuwenhuijzen et al. (2010) and Kolyaduke and
Hughes (2013) treated rats with a daily injection of
MDMA for 10 consecutive days. van Nieuwenhuijzen
et al. treated adult male Wistar rats with a daily dose of
5 mg/kg i.p. MDMA. Rats were tested 6 weeks after
MDMA treatment with a 1-hour delay between trials.
The discrimination ratio of MDMA-treated rats was
significantly less than that of saline controls. Kolyaduke
and Hughes treated male and female adolescent PVG/c
hooded rats with a higher daily dose of 10 mg/kg i.p.
MDMAduring early adolescence (postnatal days 35–45)
or late adolescence (postnatal days 45–55). Both groups
were tested as adults at no less than 90 days old (around
5–8 weeks postdrug) with a short 15-minute delay
between trials. The exploratory behavior of MDMA-
treated rats and saline controls during the test trial led
to similar discrimination indexes. The findings from
these two studies demonstrate that pretreatment with
repeated doses of MDMAmay lead to short-term recogni-
tion memory impairments at doses of 5 mg/kg but
surprisingly may have no effect at doses of 10 mg/kg. This
unexpected outcomemay be because vanNieuwenhuijzen
et al. and Kolyaduke and Hughes tested rats from
different strains, ages, and sexes.
García-Pardo et al. (2017) gave adolescent male OF1
mice four injections of 10mg/kg i.p.MDMAover 2weeks,
one on each of postnatal days 55, 57, 60, and 62. Testing
took place on postnatal day 64, 2 days after MDMA
treatment, with an ultra-short 1-minute delay between
trials. The discrimination indexes of MDMA-treated
mice and saline controls did not significantly differ,
suggesting that pretreatment with four doses of
10 mg/kg MDMA may have no later effect on short-
term recognition memory.
The following group of studies treated adolescent rats
with MDMA every 5 days (for a specific number of total
days), with multiple injections given on each treatment
day. Llorente-Berzal et al. (2013) gave male and female
Wistar rats two injections of 10 mg/kg s.c. MDMA at a
4-hour interval every 5 days from postnatal day 30–45.
Rats were tested 1 month later as adults on postnatal
day 75 with a 4-hour delay between trials. There were
no significant differences between the discrimination
indexes of MDMA-treated rats and saline controls.
These findings demonstrate that pretreatment with
repeated doses of 10 mg/kg has no subsequent effect
on long-term recognition memory. Piper and Meyer
(2004) gave male Sprague-Dawley rats two injections
of 10 mg/kg s.c. MDMA at a 4-hour interval every 5 days
from postnatal day 35 to 60. Rats were tested 1 week
later with a 15-minute delay between trials. The
Fig. 7. Dose-dependent effects of MDMA on novel object recognition.
Pretreatment with three doses of 3 mg/kg MDMA had no effect on
exploration time of the novel and familiar objects during the test trial (A)
or the discrimination ratio [novel/(novel+familiar)] (B), while pretreat-
ment with three doses of 6 mg/kg MDMA significantly decreased
exploration time of the novel object (A) and the discrimination ratio (B).
Data redrawn with permission from Fig. 3, A and C in Rodsiri et al.
(2011).
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discrimination ratio of MDMA-treated rats was signif-
icantly less than that of saline controls. Piper et al.
(2005) gavemale Sprague-Dawley rats four injections of
5 mg/kg s.c. MDMA at 1-hour intervals every 5 days
from postnatal day 35 to 60. Rats were tested 1 week
later (postnatal day 67) with a 15-minute delay and
again 1 to 2 days later (postnatal day 68 or 69) with a
30-minute delay. There were no significant differences
between the discrimination ratios of MDMA-treated
rats and saline controls under either delay condition.
The findings from these two studies are mixed; the
results of Piper et al. suggest that pretreatment with
repeated doses of 5 mg/kg MDMA has no subsequent
effect on short-term recognition memory, while the
findings of Piper and Meyer suggest that pretreatment
with repeated doses of 10 mg/kg produces short-term
recognition memory deficits. Although the same cumu-
lative daily doses were given, the difference in number
and dose of injections (two daily injections of 10 mg/kg
vs. four daily injections of 5mg/kg) could account for this
discrepancy in findings.
The next group of studies treated animals with
MDMA over several weeks. Clemens et al. (2007) gave
adult female Wistar rats a single injection of 8 mg/kg
i.p. MDMA once weekly for 16 weeks. Two days of
testing were performed 8 weeks after MDMA treatment
(with 1 day between the 2 days), and a 20-minute delay
was used for both tests. The discrimination ratio of
MDMA-treated rats and saline controls did not signif-
icantly differ during either test. In addition to testing
the effects of multiple MDMA injections on a single day
(see above), Skelton et al. (2008) gave another group of
adult male Sprague-Dawley rats the same treatment
of four injections of 15 mg/kg s.c. MDMA at 2-hour
intervals onceweekly for 5weeks. Again, ratswere tested
5 weeks after the MDMA treatment with a 1-hour
delay period. MDMA-treated rats and saline controls
explored the novel object more than the familiar object,
and there were no significant differences between
groups. Costa et al. (2014) gave male C57BL/6 mice
two injections of 10 mg/kg i.p. MDMA at a 4- to 6-hour
interval on the 2nd and 5th days of each week for
9 weeks (which started in adolescence and continued
into adulthood). Mice completed a total of 5 days of
testing—on the 6th day of drug treatment weeks 1, 4,
and 9 and posttreatment weeks 2 and 3. A 1-hour delay
was used for all five tests. The discrimination ratio of
MDMA-treated mice and saline controls did not signif-
icantly differ during drug treatment weeks 1, 4, or 9 but
was significantly reduced in MDMA-treated mice com-
pared with saline controls during posttreatment weeks
2 and 3. The findings of Clemens et al. and Skelton et al.
suggest that pretreatment with repeated doses of 8 or
15mg/kgMDMAhas no subsequent effect on short-term
recognition memory. On the other hand, the findings of
Costa et al., suggest that pretreatment with repeated
doses of 10 mg/kg MDMA has no effect on short-term
recognition memory 1 day posttreatment but produces
impairments by 2 weeks posttreatment. This discrep-
ancy may be because Costa et al. used mice as subjects
rather than rats, or possibly because the mice were
tested repeatedly throughout drug treatment.
Schulz et al. (2013) treated adolescent and adult male
Wistar rats with a varying number of s.c. MDMA
injections over 25 days. A single injection of 7.5 mg/kg
MDMA was given on 10 of the 25 days, two injections
of 7.5 mg/kg MDMA were given at a 4-hour interval on
5 of the 25 days, and no drug was given on 10 of the
25 days (treatment schedule was randomized). All rats
were tested 10 days after the 25-day treatment period,
and the adolescent rats were tested again as adults
6 weeks after the first test. Unlike the other NOR
studies reviewed here, only one object was presented
during the training trial, but the remainder of themethods
were as described above. A 25-minute delay was placed
between the training and test trials. The adult saline
controls explored the familiar object significantly less in
the test trial than the same object in the training trial, and
significantly less than the novel object in the test trial. The
adolescent saline controls, however, explored all three
objects for a comparable amount of time during the
first test. Because the adolescent saline controls did not
exhibit normal recognition memory, the effects of MDMA
cannot be accurately determined. During the second test,
the adolescent saline controls explored the familiar object
significantly less in the test trial than the same object in
the training trial (but not significantly less than the novel
object in the test trial). The adult and adolescent MDMA-
treated rats explored all three objects for comparable
amounts of time during all tests. These results suggest
that pretreatment with repeated doses of 7.5 mg/kg
MDMA during adulthood impairs short-term recognition
memory, and the same treatment during adolescencemay
produce some deficits as in adults (but the effects during
adolescence cannot be determined).
Abad et al. (2016) gave adolescentmale C57BL/6mice
three injections of s.c. MDMA at 1-hour intervals once
weekly for 8 weeks—at doses of 5 mg/kg MDMA for the
first 2 weeks, 7.5 mg/kg MDMA for the next 3 weeks,
and 10 mg/kg MDMA for the last 3 weeks. Mice were
tested as adults, 1 week and 3 months after MDMA
treatment with 1- and 24-hour delays. The discrimina-
tion indexes of MDMA-treated mice and saline controls
did not significantly differ with a 1-hour delay but was
significantly reduced in MDMA-treated mice compared
with saline controls with a 24-hour delay at both 1 week
and 3 months posttreatment. These findings suggest
that pretreatment with repeated doses of MDMA (in-
creasing from 5 to 10 mg/kg) has no subsequent effect
on short-term recognition memory but may lead to long-
term recognition memory deficits.
a. Novel object recognition variations. Pompei et al.
(2002) and Skelton et al. (2008) tested the effects of
MDMA on a novel place recognition (NPR) test and a
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social recognition (SR) test, respectively, and these
studies are outlined in Table 4. The procedures of these
tests are similar to the NOR test, but the NPR test
assesses recognition memory of an object’s orientation
and the SR test assesses recognition memory of
another animal. In the NPR test, the two objects
presented in the training trial are identical to those
presented in the test trial, but in the test trial one
object is placed 90° clockwise compared with its
location in the training trial. The exploration time of
each object is recorded during both trials, and recognition
memory is revealed by significantly less exploration of the
non-rotated object comparedwith the rotated object in the
test trial or either object in the training trial. In the SR
test, a juvenile rat is introduced into the cage of an adult
male rat (the test subject) in the training trial, and the
same juvenile rat is reintroduced into the cage of the adult
in the test trial. The time that the adult rat spends
exploring the juvenile rat (i.e., nosing, sniffing, grooming,
pawing, or close following) is recorded during both trials. A
decrease in exploration time from the training trial to the
test trial reflects recognition memory of the juvenile rat.
Skelton et al. (2008) gave adult male Sprague-Dawley
rats four injections of 15 mg/kg s.c. MDMA at 2-hour
intervals on a single day or once weekly for 5 weeks.
Testing took place 40 days after MDMA treatment with
a 1-hour delay between trials. MDMA-treated rats did
not significantly differ from saline controls on any
measure of object exploration. This suggests that pre-
treatment with repeated doses of 15 mg/kg MDMA has
no later effect on short-term recognition memory.
Pompei et al. (2002) gave adult male Sprague-Dawley
rats a daily injection of 1, 5, or 10 mg/kg i.p. MDMA for
8 consecutive days. The SR test took place on the 8th
day of MDMA treatment. Rats were given their final
MDMA injection immediately after the training trial
and tested after a 120-minute delay. All groups explored
the juvenile rat less in the test trial than in the training
trial. This decrease in exploration time was signifi-
cantly enhanced in rats given 1 or 5 mg/kg MDMA
injections compared with saline controls and did not
significantly differ between rats given 10 mg/kg MDMA
injections and saline controls. These findings reveal
that pretreatment with repeated doses MDMA may
enhance short-term recognition memory at doses of 1 or
5 mg/kg MDMA (although the authors’ conclusions are
inconsistent with their graphical data) andmay have no
effect on short-term recognition memory at a dose of
10 mg/kg MDMA when memory consolidation and
retrieval occur on-drug.
2. Other Nonspatial Tasks.
a. Cincinnati water maze. The Cincinnati water
maze (CWM) task (Vorhees, 1987) is a nonspatial
variation of the MWM task. The CWM is a 9-unit
multiple T-maze that is filled with water. Animals are
required to swim through the maze to escape onto a
hidden platform. The maze is configured so that the path
to the goal runs along only the long arms of eachT.Testing
is performed under red light or complete darkness to limit
or eliminate the use of distal visual cues, and therefore
animals must rely on egocentric cues to navigate to the
hidden platform. Typically, each animal completes two
trials per day for several days. The starting location of the
animal and the platform location remain constant over all
trials and days. The escape latency (i.e., time taken to
reach the hidden platform) and number of errors (i.e.,
entries into one of the short arms of a T) are recorded
during all trials. A decrease in escape latency/number of
errors over the days of testing reflects nonspatial learning
of the platform location.
Three studies assessed the effects of MDMA on the
CWM task, which are listed in Table 4. Prior to testing,
Able et al. (2006), Skelton et al. (2008), and Vorhees
et al. (2011) all gave adult male Sprague-Dawley rats
four injections of 15 mg/kg s.c. MDMA at 2-hour
intervals on a single day, and Skelton et al. gave
another group of rats this same treatment once weekly
for 5weeks. Able et al. began testing 4 days afterMDMA
treatment and tested rats for a total of 6 days. The rate
at which the number of errors and escape latency of
MDMA-treated rats decreased over the 6 testing days
was slower than that of saline controls. Specifically,
MDMA-treated rats made significantly more errors
than saline controls on days 4 and 5, and a trend toward
significantly more errors on day 6. Skelton et al. began
testing 1 week after MDMA treatment and tested rats
for a total of 6 days. While the average number of errors
and the average escape latency of MDMA-treated rats
(both single day and weekly) were significantly higher
than saline controls, these measures decreased at a
similar rate over the 6 testing days in all three groups.
Both groups of MDMA-treated rats therefore exhibited
performance impairments but not learning impair-
ments. Vorhees et al. began testing 2 weeks after
MDMA treatment and tested rats for a total of 21 days.
The number of errors and escape latency of MDMA-
treated rats and saline controls decreased at a similar
rate over the 21 testing days, and the overall average
number of errors and average escape latency also did
not significantly differ between groups. The findings
from these three studies reveal pretreatment with
repeated doses of 15 mg/kg MDMA has no effect on
nonspatial learning when tested 1 week or more
after treatment but produces nonspatial learning
impairments when testing begins less than 1 week
after treatment.
E. Fear-Motivated Learning and Memory
1. Passive Avoidance. The passive avoidance (PA)
task is a fear-motivated task that is used to evaluate
learning and memory in rodents. A common version of
this task is the step-through PA task (Jarvik and Kopp,
1967), which takes place in a two-compartment cham-
ber consisting of one bright (e.g., illuminated, white
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walls) compartment and one dark (e.g., nonilluminated,
black walls) compartment connected by a guillotine
door. The task requires animals to inhibit their natural
tendency to prefer dark areas/avoid bright areas to
avoid an aversive stimulus. Each animal is first habit-
uated to both compartments of the chamber as well as
crossing through the guillotine door prior to training.
Training is usually completed in a single trial, which
begins by placing the animal in the bright compartment
with the guillotine door closed. After a brief period, the
guillotine door is opened, and once the animal enters
the dark component, the guillotine door is closed, and
the animal receives an inescapable foot shock. Testing
typically takes place 24 hours after training, during
which the animal is returned to the bright compart-
ment, and again the guillotine door is opened after a
brief period. If the animal remembers that entering the
dark compartment lead to a foot shock during training,
then the animal will inhibit its natural tendency to
enter the dark compartment.
The step-through latency (i.e., time taken to enter the
dark compartment once the guillotine door is opened) is
measured during both the training and test trials, and
the cutoff time/maximum latency recorded is usually
300 seconds. A significant increase in step-through latency
from training to testing reflects normalmemory retention,
whereas the lack of this increase reflects memory deficits.
A significantly lower step-through latency relative to
normal during testing is also an indicator of memory
deficits. The type of memory measured here involves both
explicit memory (i.e., association with the context) and
implicit memory (i.e., operant conditioning to the shock).
Table 5 lists the 12 studies that explored the effects
of MDMA on the PA task. Eleven of these studies
conducted the step-through PA task, whereas only one
study (McNamara et al., 1995) performed another
version, the step-down PA task (methods described
below). The animals from most of these studies were
treated with MDMA 1 or more days prior training,
30 minutes before training, and/or immediately after
training. All of the studies evaluated long-term mem-
ory as delays of 24 hours or more were placed between
the training and test trials.
Moyano et al. (2004, 2005) and Barrionuevo et al.
(2000) all tested the effects of on-drug training. Adult
maleWistar rats were given a single injection of MDMA
30 minutes before training and then tested 24 hours
later. Moyano et al. (2004, 2005) found that rats injected
with 10 mg/kg i.p. MDMA before training exhibited a
significantly lower step-through latency than saline con-
trols during testing, and Barrionuevo et al. (2000) found
the same results with a dose of 20 mg/kg i.p. MDMA.
These findings suggest that doses of 10 and 20 mg/kg
MDMA produce long-term memory deficits when mem-
ory acquisition occurs on-drug.
Shariati et al. (2014) and Budzynska et al. (2017)
explored the effects of administering the drug
immediately after training. Figure 8 exhibits the find-
ings of Budzynska et al., which exemplify the dose-
dependent effects of MDMA on fear-motivated learning
and memory. Budzynska et al. gave adult male Swiss
Webster mice a single injection of 1, 2.5, 5, or 10 mg/kg
i.p. MDMA immediately after training and tested the
mice 24 hours later. The step-through latency of mice
treated with 1 or 10 mg/kg MDMA did not signifi-
cantly differ from that of saline controls, while mice
treated with 2.5 or 5 mg/kg MDMA showed a signifi-
cantly higher step-through latency than saline controls.
Shariati et al. tested two groups of adult male Wistar
rats—one group received a single injection of 10 mg/kg
i.p. MDMA following two training trials, and another
group received a daily injection of 10 mg/kg i.p. MDMA
on 2 consecutive days per week for 3 weeks, with the last
injection administered immediately following training.
All rats were tested 24 hours after MDMA treatment,
and both groups of MDMA-treated rats demonstrated a
significantly shorter step-through latency than saline
controls. Together, the above results indicate that
administering MDMA immediately after memory ac-
quisition has no effect on long-term memory retention
at a dose of 1 mg/kg but enhances long-term memory
retention at doses of 2.5 or 5 mg/kg. The findings
regarding a dose of 10 mg/kg MDMA are mixed, as
Budzynska et al. found that this dose has no effect on
long-termmemory retention, while Shariati et al. found
that single or repeated administration of this dose impairs
long-term memory retention. This discrepancy could be
due to the use of different species (mice vs. rats) or the
number of training trials (one vs. two).
Jahanshahi et al. (2013) also treated young adult
male Wistar rats with MDMA between training and
testing, but the MDMA treatment began 24 hours after
two training trials and lasted for 4 weeks. Rats were
given three injections of 2.5, 5, or 10 mg/kg i.p) MDMA
at 3-hour intervals once weekly for 4 weeks. Testing
took place following drug treatment, and all three
groups of MDMA-treated rats exhibited a significantly
longer step-through latency than saline controls. These
results reveal that treatment with doses of 2.5, 5, and
10 mg/kg MDMA after acquisition may enhance long-
term memory retention.
The next group of studies treated animals with a
specific MDMA regimen prior to training and testing.
Timár et al. (2003) and Murnane et al. (2012) gave
animals four injections of MDMA at 2-hour intervals.
Timár et al. gave adolescent male Wistar rats doses of
10mg/kg s.c.MDMAand tested them3 days and 4weeks
after MDMA treatment, with 48 hours separating train-
ing and testing. During both tests, MDMA-treated rats
and saline controls did not significantly differ in step-
through latency. Murnane et al. gave adolescent male
Swiss Webster mice doses of 10 or 20 mg/kg i.p. MDMA.
Rats were trained 2 days after MDMA treatment and
tested 2 days after training. Again, MDMA-treated rats
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and saline controls did not significantly differ in step-
through latency. In all, these studies reveal that pre-
treatment with four doses of 10 or 20 mg/kg MDMA has
no subsequent effect on long-term memory retention.
In addition to testing the effects of on-drug training
(see above), Moyano et al. (2005) gave another group of
adult male Wistar rats two daily injections of 10 mg/kg
i.p. MDMA for 4 consecutive days. Rats were trained
1 week after MDMA treatment and tested 24 hours
after training. The step-through latency of MDMA-
treated rats and saline controls did not significantly
differ. Moyano et al. tested an additional group, which
received both of the previously described treatments,
two daily injections of 10 mg/kg i.p. MDMA for 4 consec-
utive days, 1 week prior to training, and a single
injection of 10 mg/kg i.p. MDMA, 30 minutes before
training. This group of MDMA-treated rats exhibited a
significantly slower step-through latency than saline con-
trols. Together these findings suggest that pretreatment
with repeated doses of 10mg/kgMDMAhas no subsequent
effect on long-term memory retention, while a single dose
of 10 mg/kg MDMA impairs long-term memory retention
when memory acquisition occurs on-drug.
García-Pardo et al. (2015, 2017) gave adolescent male
OF1 mice a single injection of 10 mg/kg i.p. MDMA on
four alternating days (2 to 3 days between each injec-
tion). García-Pardo et al. (2015) trained their mice
4 days after MDMA treatment and García-Pardo et al.
(2017) trained their mice 5 days after MDMA treat-
ment, and all mice were tested at 24 hours and 1 week
after training. Both studies had identical findings—the
step-through latency of MDMA-treated mice did not
change significantly from training to testing (24 hours
and 1 week later), and the step-through latency of
MDMA-treatedmice was significantly shorter than that
of saline controls at 1 week after training (but not at
24 hours). These findings suggest that pretreatment
with four doses of 10 mg/kg MDMA leads to long-term
memory impairments that are more significant at
1 week versus 24 hours after acquisition.
Rodríguez-Arias et al. (2011) gave adolescent male
OF1 mice two daily injections of 10 or 20 mg/kg i.p.
MDMA at a 4-hour interval on 2 consecutive days per
Fig. 8. Dose-dependent effects of MDMA on passive avoidance. Posttraining
doses of 2.5 and 5 mg/kg MDMA enhanced long-term memory, while
posttraining doses of 1 and 10 mg/kg MDMA had no effect on long-term
memory. Data redrawn with permission from Fig. 5 in Budzynska et al. (2017).
TABLE 5
Studies examining the effects of MDMA on fear-motivated learning and memory
Article Taska Subjectsb Doses/Frequencyc Timelined Effectse
Moyano et al., 2004 PA Rats (W), Adult, Male 10 mg/kg (i.p.)  1 Training: On-Drug
Testing: Postdrug
↓
Moyano et al., 2005 PA Rats (W), Adult, Male 10 mg/kg (i.p.)  1 AND/OR
 2/day, 4 days
Training: On-Drug (Single),
Postdrug (Repeated)
Testing: Postdrug
↓ (Single)
⌀ (Repeated)
Barrionuevo et al., 2000 PA Rats (W), Adult, Male 20 mg/kg (i.p.)  1 Training: On-Drug
Testing: Postdrug
↓
Budzynska et al., 2017 PA Mice (SW), Adult, Male 1, 2.5, 5, or 10 mg/kg (i.p.)  1 Training: Off-Drug2
Testing: Postdrug
↑ (2.5 and 5 mg/kg)
⌀ (1 and 10 mg/kg)
Shariati et al., 2014 PA Rats (W), Adult, Male 10 mg/kg (i.p.)  1 OR  1/day,
2 day/wk, 3 wk
Training: Off-Drug2
Testing: Postdrug
↓
Jahanshahi et al., 2013 PA Rats (W), Adult, Male 2.5, 5, or 10 mg/kg (i.p.)  3/day,
1 day/wk, 4 wk
Training: Predrug
Testing: Postdrug
↑
Timár et al., 2003 PA Rats (W), Adol., Male 10 mg/kg (s.c.)  4 Training/Testing: Postdrug ⌀
Murnane et al., 2012 PA Mice (SW), Adol., Male 10 or 20 mg/kg (i.p.)  4 Training/Testing: Postdrug ⌀
García-Pardo et al., 2015 PA Mice (OF1), Adol., Male 10 mg/kg (i.p.)  1/day, 4 days
(spaced)
Training/Testing: Postdrug ↓
García-Pardo et al., 2017 PA Mice (OF1), Adol., Male 10 mg/kg (i.p.)  1/day, 4 days
(spaced)
Training/Testing: Postdrug ↓
Rodríguez-Arias et al.,
2011
PA Mice (OF1), Adol., Male 10 or 20 mg/kg (i.p.)  2/day,
2 days/wk, 2 wk
Training/Testing: Postdrug ⌀
McNamara et al., 1995 PA Rats (SD), Adult, Male 5, 10, or 20 mg/kg (i.p.)  2/day,
4 days
Testing: Postdrug ⌀
Shortall et al., 2013 FC Rats (LH), Adult, Male 10 mg/kg (i.p.)  1/day, 3 days
(spaced)
Training: Off-Drug2
Testing: Postdrug
⌀
Johansson et al., 2015 FC Mice (ICR), Adult, Male 20 mg/kg (i.p.)  2 Training/Testing: Postdrug ↓
aStudies used the passive avoidance (PA) and contextual fear conditioning (FC) tasks.
bSpecies (strain), age, and sex of subjects. Strains include Lister Hooded (LH), Sprague-Dawley (SD), and Wistar (W) rats; and ICR, OF1, and Swiss Webster (SW) mice.
cDose, route, and frequency of MDMA administration. Treatment days/weeks are consecutive unless noted as “spaced.”
dWhen training and testing occurred in relation to drug treatment. Pre- and post-drug training/testing were always conducted off-drug.
eEffects of drug treatment on learning and memory: ⌀ No Effect, ↓ Impairment, ↑ Enhancement.
2Off-drug training/testing took place immediately before drug administration on (last) day of treatment.
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week for 2 weeks. Mice were trained 22 days after
MDMA treatment and tested 24 hours later. The step-
through latency of MDMA-treated mice and saline
controls did not significantly differ, revealing that pre-
treatment with repeated doses of 10 or 20mg/kgMDMA
may have no subsequent effect on long-term memory.
Unique to the other studies reviewed here, McNamara
et al. (1995) tested adult male Sprague-Dawley rats on
the step-down version of the PA task. Rats were given
two daily injections of 5, 10, or 20 mg/kg i.p. MDMA at a
12-hour interval for 4 consecutive days and tested 6 days
later. On each trial, a rat was placed on a triangular
platform that was mounted above a grid floor. When the
rat stepped off the platform, it received a foot shock.
Repeated trials were conducted until the rat remained
on the platform for at least 2 minutes. MDMA-treated
rats and saline controls did not significantly differ in the
number of trials it took for them to reach this threshold,
suggesting that pretreatment with repeated doses of 5,
10, or 20mg/kgMDMAhas no effect onmemory function.
2. Contextual Fear Conditioning. The contextual
fear conditioning (FC) paradigm (Fanselow, 1986;
Anagnostaras et al., 1999, 2010, 2015) is an efficient
model tomeasure hippocampal-dependent learning and
memory in rodents. In contextual FC, an animal learns
to associate an aversive stimulus (typically a foot shock)
with a specific context. As a result, the initially neutral
context elicits a fear response in the animal. In rodents,
this fear response arises as freezing behavior, which is a
measure of contextual fear memory. Thus a significant
decrease in freezing is indicative of memory deficits.
Two studies explored the effects ofMDMAon contextual
FC and are outlined in Table 5. These studies used two
different variations of the typical FC procedure, which
are described below.
Shortall et al. (2013) conducted a “conditioned emo-
tional response” task, which is a variation of the contex-
tual FC task. The task took place in a two-compartment
box that consisted of a dark side and a light side
separated by a computer-operated door. For training,
each animal was placed on the light side of the box, and
after 30 seconds the door was opened. When the animal
entered the dark side of the box, the door was closed,
and the animal was subject to two light/tone and foot-
shock pairings (a 5-second light and tone cue that
coterminatedwith a 1-second foot shock)with a 1-minute
interval between pairings. For testing, each animal was
returned to the dark side of the box, and freezing was
measured for 5-minute without any light/tone or foot
shock presentation. In this study, young adult male
Lister Hooded rats were given a single injection of
10 mg/kg i.p. MDMA on experiment days 1, 2, and 8. Rats
were trained on experiment day 8 immediately prior to
MDMA treatment and tested 24 hours later. MDMA-
treated rats and saline controls did not significantly differ
in freezing timeduring the test. These results suggest that
treatment with repeated doses of 10 mg/kg MDMA prior
to and followingmemory acquisition has no effect on long-
term context memory.
Johansson et al. (2015) performed another variation
of the contextual FC task, contextual fear discrimina-
tion. This task took place in two contexts, Context A
and Context B, which differed by a variety of sensory
modalities (different floor/walls, noise, illumination,
and scent). Training took place in Context A, and each
animal completed one training trial per day for 3 days.
For each trial, the animal was introduced to Context A,
and after a 3-minute baseline period they received a
2-second foot shock and then remained in the context for
an additional 15 seconds. Testing began 3 days later,
and each animal was exposed to both Context A and
Context B on all 12 days of testing (random order of
exposure with a 1.5- to 2-hour interval between each
exposure). The trials in Context A were identical to
training (3-minute baseline + 2-second foot shock +
15-second postshock period), and the trials in Context B
were 3 minutes in duration with no foot shock. In this
study, adult male ICR mice were given two injections of
20 mg/kg i.p. MDMA at a 2-hour interval, 4 days prior
to training. The freezing behavior of saline controls
increased significantly in Context A and decreased
significantly in Context B over the 12 days of testing and
overall was significantly greater in Context A than in
Context B on the last 8 days of testing. Conversely, the
freezing behavior of MDMA-treated rats remained
constant over the 12 days of testing and did not
significantly differ between Context A and Context B.
These results suggest that pretreatment with two doses
of 20 mg/kg MDMA leads to later deficits in learning to
discriminate between two contexts.
VI. Analysis of Findings
This review includes a total of 90 experiments on the
cognitive effects of MDMA in animals. Clearly, findings
are mixed on whether MDMA impairs, enhances, or has
no effect on cognition. Figure 9 depicts the breakdown
of findings from all experiments reviewed here. Of
the 90 total experiments, MDMA produced cognitive
enhancements in one experiment, mixed parameter-
dependent cognitive enhancements/no effects in three
experiments, no cognitive effects in 46 experiments,
mixed parameter-dependent impairments/no effects in
17 experiments, and cognitive impairments in 23 exper-
iments.2 MDMA produced cognitive impairments in
2All experiments in the current review were categorized by
whether MDMA treatment produced: 1) impairments, 2) a mix of
impairments and no effects, 3) no effects, 4) a mix of no effects and
enhancements, 5) enhancements. The “mixed” categories (2 and 4)
include experiments with findings that are inconsistent across
different treatment and/or task parameters (e.g., MDMA dose,
frequency of drug administration, experimental timeline, etc.).
See Tables 1–5 (“Effects” columns) for examples of experiments
with mixed findings.
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only 40 of the 90 experiments (44.4%), and in 17 of these
experiments only certain parameters led to impair-
ments. Thus MDMA did not influence cognition in the
majority of these experiments, even when dose is
ignored. MDMA did not produce any cognitive im-
pairments in 50 of the 90 experiments (55.6%), and
an additional 17 experiments showed negligible effects
under certain parameters. Therefore, some negligible
effects were found in 74.4% of all experiments. To better
understand these findings, we further analyze the
factors that may modulate the cognitive effects of
MDMA.
A. Findings by Cognitive Domain
We first analyze the findingswithin eachmajor section
—attention (2 studies), working memory (23 studies),
spatial learning and memory (24 studies), nonspatial
learning and memory (27 studies), and fear-motivated
learning and memory (14 studies). Figure 10 illustrates
the breakdown of findings by cognitive domain.
The effects of MDMA on attention were examined in
two studies on the 5-CSRT task (Table 1). Taffe et al.
(2001) found that MDMA produced attention deficits
on-drug but no effects postdrug, and Taffe et al. (2002)
found that MDMA produced no effects postdrug. There-
fore, it appears that MDMA produces attention deficits
when on-drug but not following drug treatment. How-
ever, there are not enough studies to reach a definitive
conclusion of these findings.
The effects of MDMA on working memory were
examined in 23 studies using the DMS/DNMS, OST,
SA/DA, RAM, or MWM tasks (Table 2). Of these
23 studies, 19 found no effects on working memory,
three found no effects at doses of 1.25–3 mg/kg and
working memory impairments at doses of 3–5 mg/kg,
and one found working memory impairments only (Fig.
10A). Thus the majority of these studies found that
MDMA treatment does not alter working memory.
While Braida et al. (2002), Young et al. (2005), and Kay
et al. (2010) found that doses of 3–5 mg/kg impair
spatial working memory while on-drug, most of the
studies with similar testing parameters found no effects
on spatial working memory. In Wistar rats, the on-drug
effects appear to be dose-dependent, as doses of 1–
2.25 mg/kg had no effects but doses of 3–5 mg/kg
impaired spatial working memory (Braida et al.,
2002; Young et al., 2005). Marston et al. (1999) found
that treatment with doses of 10–20 mg/kg leads to
postdrug working memory impairments, but several
other studies concluded that similar treatments lead
to no postdrug effects. In all, it appears that MDMA
generally has no on-drug or postdrug impact on
working memory.
The effects of MDMA on spatial learning andmemory
were explored in 24 studies using the MWM, RAM, and
SD tasks (Table 3). Of these 24 studies, one found
spatial learning enhancements and no effect on spatial
reference memory, eight found no effects on spatial
learning and memory, six found a mix of no effects
and spatial learning and memory impairments (impair-
ments found with doses of 3–5.6 mg/kg but not 0.3–
1.7 mg/kg, spatial reference memory but not spatial
learning, or later postdrug testing), and nine found
spatial learning and memory impairments only (Fig.
10B). Here, the slight majority of studies found impair-
ments, but the true effect of MDMA on spatial learning
and memory remains unclear. The effects of on-drug
training and/or testing appear to be dose-dependent yet
differ by strain. In Wistar rats, doses of 1.25–5 mg/kg
had no effects (Young et al., 2005) and doses of 5–15
produced impairments (Taghizadeh et al., 2016). In
Sprague-Dawley rats, doses of 0.3–1.7 mg/kg had no
effects (Kay et al., 2010; Galizio et al., 2014) and doses
of 3–5.6 mg/kg produced impairments (Kay et al., 2010,
2011; Harper et al., 2013; Galizio et al., 2014). The
postdrug findings remain mixed, as there is evidence
that highly similar/identical experimental designs pro-
duced dissimilar effects. In the MWM studies, spatial
reference memory during the probe test appears to be
more sensitive to impairment than spatial learning
during acquisition. Overall, these findings reveal that
the effects of MDMA on spatial learning and memory
while on-drug may be dose-dependent but the post-
drug effects are still unclear.
The effects of MDMA on nonspatial learning and
memory were explored in 27 studies using the NOR,
NPR, SR, and CWM tasks (Table 4). Of these 27 studies,
one found nonspatial learning and memory enhance-
ments at doses of 1 and 5 mg/kg and no effects at a dose
of 10 mg/kg, 13 found no effects, 6 found a mix of no
effects and nonspatial learning and memory impair-
ments (impairments found with a dose of 6 mg/kg
but not 3 mg/kg, more drug administrations, longer
delay periods, or later postdrug testing), and 7 found
nonspatial learning and memory impairments only
Fig. 9. Breakdown of findings from all 90 experiments. Most experiments
(46 out of 90) found no effects of MDMA on cognition.
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(Fig. 10C). Thus the majority of studies found no effects
on nonspatial learning and memory. There appears to
be no precise reason for the observed impairments, as
studies with almost identical methods produced no
effects in other cases. There does appear to be a lesser
rate of impairments in Sprague-Dawley rats than in the
other strain/species. In all, the evidence suggests that
MDMA likely has no effect on nonspatial learning and
memory, but the reasons for occasional impairments are
ambiguous.
The effects of MDMA on fear-motivated learning and
memory were examined in 14 studies using the PA and
FC tasks (Table 5). Of these 14 studies, one found
memory enhancements, one found memory enhance-
ments at doses of 2.5 and 5mg/kg and no effects at doses
of 1 and 10 mg/kg, 5 found no effects, 1 found no effects
with postdrug training and memory impairments with
on-drug training, and 6 found memory impairments
only (Fig. 10D). Here, on-drug training always impaired
memory acquisition, but only high doses of 10–20 mg/kg
were tested. Administration ofMDMAbetween training
and testing enhanced or had no effect on memory
consolidation at doses of 2.5–10 mg/kg and impaired
or had no effect on memory consolidation at doses of
10–20 mg/kg. Postdrug training and testing most often
resulted in no effects. In all, the effects of MDMA on
fear-motivated learning and memory are mixed but
appear to be highly dependent on dose and when the
drug is administered.
Overall, this review reveals that MDMA likely has no
effect on working memory and nonspatial learning and
memory and may or may not impair spatial learning
and memory and fear-motivated learning and memory.
The reasons for these ambiguous findings may be
revealed through further analyses.
B. Findings by Dose
With respect to typical, occasional users of MDMA
and its potential for therapeutic use, an examination of
the impact of low, clinically and community-relevant
dosing is essential. To examine the role of dose in the
cognitive effects of MDMA, we divided all experiments
into four groups by dose of MDMA administered—less
than 3, 3–6, 7.5–10, and 15–30 mg/kg. Given the
average human weight of 70 kg, these levels correspond
to less than 210, 210–420, 525–700, and 1050–2100 mg.
Of the studies reviewed here, 15 experiments adminis-
tered doses of less than 3 mg/kg, 31 experiments
administered doses of 3–6 mg/kg, 50 experiments ad-
ministered doses of 7.5–10 mg/kg, and 31 experiments
administered doses of 15–30 mg/kg (note: some exper-
iments used a range of doses, and the totals above
account for experiments that administered doses from
multiple levels). Figure 11 illustrates the breakdown of
findings by these dose categories. Of these it is impor-
tant to note that only the lowest dose range (,3 mg/kg)
seems to reflect the doses taken by most recreational
MDMA users (i.e., 1 to 2 mg/kg), and it is likely that
any potential therapeutic dosing would be even lower.
Although there are several studies in this dose
range, there are very few that examine microdosing
(e.g., ,1 mg/kg). At these doses, MDMA may have high
therapeutic value and will almost certainly pose even
less risk. Therefore, we suggest more studies, both
human and animal, to examine MDMA at microdose
ranges (e.g., ,1 mg/kg).
Perhaps the most important finding from this review
is that there is no evidence that doses below 3 mg/kg
MDMA, the doses that people ordinarily take, produce
cognitive impairments in animals, even when the
animals are on-drug (Fig. 11A). Doses of 0.1, 0.3, 0.32,
0.75, 1.0, 1.25, 1.7, 1.75, 1.8, 2.0, and 2.25 mg/kg
produced no effects on working memory when animals
were tested on-drug on the DMS (LeSage et al., 1993;
Frederick et al., 1995a,b; Harper et al., 2005), OST
(Hawkey et al., 2014), DA (Young et al., 2005), RAM
(Braida et al., 2002; Kay et al., 2010), or MWM (Galizio
et al., 2014) tasks. Doses of 0.3, 0.75, 1.0, 1.25, 1.7, and
2.25 mg/kg produced no effects on spatial learning and
memory when animals were tested on-drug on the
Fig. 10. Breakdown of findings from 23 working memory (A), 24 spatial learning and memory (B), 27 nonspatial learning and memory (C), and 14 fear-
motivated learning and memory (D) experiments.
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MWM (Galizio et al., 2014), RAM (Kay et al., 2010), or
SD (Young et al., 2005) tasks. A dose of 1 mg/kg
produced recognition memory enhancements when
administered immediately after training / before on-
drug testing on the SR task (Pompei et al., 2002). A
dose of 1 mg/kg had no effect on memory and a dose
of 2.5 mg/kg produced memory enhancements when
administered between training and testing on the PA
task (Jahanshahi et al., 2013; Budzynska et al., 2017).
Evidently, doses of less than 3 mg/kg MDMA only led
to no effects or memory enhancements in the studies
reviewed here.
The majority of the studies reviewed here used
unrealistically high MDMA doses of 3 mg/kg or greater.
Doses of 10, 15, and 20 mg/kg were very common, as
69 of the 90 experiments studied the effects of one of
these three doses. In an average human of 70 kg,
10mg/kg is equivalent to 700mg, 15mg/kg is equivalent
to 1050 mg, and 20 mg/kg is equivalent to 1400 mg.
Given that the average humanMDMA dose is about 1 to
2mg/kg, these animal doses are 5–20 times greater than
the doses taken by typical human users. Alternatively,
this can be regarded as taking up to 20 MDMA tablets
(each tablet = about 1mg/kg) at one time, overdoses that
would likely cause shock and alarm even among heavy
users. In 48 of the 69 high-dose ($3mg/kg) experiments,
doses of 10, 15, or 20 mg/kg were administered multiple
(2–4) times per day. Twice daily administration of these
doses is comparable to taking 20, 30, or 40 MDMA
tablets in 1 day. Cohen et al. (2005), Able et al. (2006),
Skelton et al. (2008), Vorhees et al. (2011), and
Viñals et al. (2012), gave rodents extreme treatments
of 60 mg/kg per day, which is equivalent to a human
taking 4200 mg of MDMA or 60 MDMA tablets per day.
The most extreme MDMA treatment was delivered by
Murnane et al. (2012), who gave rodents a total of
80mg/kg per day, which is equivalent to a human taking
5600 mg of MDMA or 80 MDMA tablets per day.
These doses clearly do not reflect typical MDMA use
in humans, and the validity of high-dose findings,
outside of understanding very heavy users, should be
of concern. It is somewhat misleading to portray the
“typical” toxic effects of a drug based on what is
essentially a 5–20 overdose. If those criteria were
applied to other drugs, many existing therapeutics
would be regarded as very unsafe, even lethal, including
all of the statins, most antihypertensives, selective
serotonin reuptake inhibitors, and even acetaminophen
(paracetamol) (see Larson et al. (2005) for more about
the high incidence and seriousness of acetaminophen
overdose).
Regardless of the extreme MDMA treatments given
to animal subjects, the findings on the cognitive effects
of high-dose MDMA remains somewhat unconvincing.
Of the 31 experiments that gave doses of 3–6 mg/kg,
11 found impairments, 4 found a mix of impairments
and no effects depending on task parameters, 13 found
no effects, and 3 found enhancements (Fig. 11B). Of the
50 experiments that gave doses of 7.5–10 mg/kg,
13 found impairments, seven found a mix of impair-
ments and no effects depending on task parameters,
29 found no effects, and one found enhancements (Fig.
11C). Of the 31 experiments that gave doses of 15–
30 mg/kg, 11 found impairments, 2 found a mix of
impairments and no effects depending on task param-
eters, 17 found no effects, and 1 found amix of no effects
and enhancements depending on task parameters (Fig.
11D). Thus the administration of 3–30 mg/kg MDMA
led to cognitive impairments in only less than half
of experiments. Overall, the most compelling evidence
of high-dose ($3 mg/kg) MDMA-induced impairments
is in spatial referencememory (assessed via theMWM
probe and the RAM) and fear-motivated memory
acquisition (assessed via on-drug PA training); high
doses did not consistently lead to impairments in any
other cognitive domain (e.g., nonspatial learning and
memory).
In all, we found no evidence that low, clinically and
community-relevant doses of MDMA (,3 mg/kg) pro-
duce cognitive impairments in animals. The findings
Fig. 11. Breakdown of findings from experiments that administered MDMA at doses of less than 3 mg/kg [(A); n = 15], 3–6 mg/kg [(B); n = 31], 7.5–
10 mg/kg [(C); n = 50], and 15–30 mg/kg [(D); n = 31]. There is no evidence that MDMA produces cognitive impairments at doses below 3 mg/kg (A), and
the evidence regarding doses of 3–30 mg/kg is mixed (B–D).
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regarding higher doses ($3 mg/kg) are mixed yet led to
cognitive impairments in less than half of experiments,
whichwere primarily in the cognitive domains of spatial
and fear-motivated learning and memory. Across all
experiments, we did not find differences in effects based
on route or frequency of administration. While heavy
MDMA users, which account for only a small fraction of
users, may use potentially memory-impairing doses
($3 mg/kg), typical recreational and therapeutic doses
lie below this range and did not produce cognitive
deficits in any animal study.
C. Findings by When the Drug Was Administered
Here, we consider the effects of MDMA on learning
and memory (all experiments except those on attention
or working memory) with respect to when the drug was
administered. Findings are categorized by whether
MDMA was administered during training, between
training and testing, during testing, or entirely prior
to training and testing.
The effects of MDMA on memory acquisition are
determined by on-drug training. Findings from the five
experiments that conducted on-drug training (and
then off-drug testing) reveal a clear dose-dependent
effect of MDMA on memory acquisition. Doses of 0.3,
1, and 1.7 mg/kg had no effect on memory acquisition
(Galizio et al., 2014), while doses of 3–20 mg/kg
impaired memory acquisition (Barrionuevo et al.,
2000; Moyano et al., 2004, 2005; Galizio et al., 2014;
Taghizadeh et al., 2016).
The effects of MDMA on memory consolidation are
determined by administering the drug between training
and testing (typically immediately after training).
Findings from the six experiments that administered
MDMA after training yet before off-drug testing again
present a dose-dependent effect on memory consolida-
tion. Doses of 2.5, 5, and 10 mg/kg enhanced memory
consolidation (Jahanshahi et al., 2013; Budzynska
et al., 2017), while doses of 1 and 10 mg/kg also had no
effect on memory consolidation (Shortall et al., 2013;
Budzynska et al., 2017).Higher doses of 10 and 20mg/kg
impaired memory consolidation (Ros-Simó et al., 2013;
Shariati et al., 2014).
The effects of MDMA on memory retrieval are deter-
mined by on-drug testing. Findings from the four
experiments that conducted on-drug testing (but off-
drug training) again exhibit a dose-dependent effect of
MDMA on memory retrieval. Doses of 0.75, 1.25, 2.25,
and 5 mg/kg had no effect on memory retrieval (Young
et al., 2005; Kay et al., 2010), while doses of 3 and
4 mg/kg impaired memory retrieval (Kay et al., 2010;
Kay et al., 2011; Harper et al., 2013). Different rat
strains (Sprague-Dawley vs. Wistar) may account for
the contradictory effects of doses in the 3–5mg/kg range
(specifically, the 5 mg/kg outlier).
Pompei et al. (2002) administered MDMA immedi-
ately after training, and testing took place 2 hours later
on-drug. In this design, both memory consolidation and
retrieval could be influenced by MDMA. Doses of 1 and
5 mg/kg enhanced memory consolidation/retrieval,
while a dose of 10 mg/kg had no effect on memory
consolidation/retrieval. Additionally, Shortall et al.
(2013) administered MDMA before training and con-
ducted testing 2 hours later so both training and testing
occurred on-drug. In this case, MDMA could influence
memory acquisition, consolidation, and retrieval. A
dose of 10 mg/kg impaired memory acquisition/
consolidation/retrieval.
Experiments in which memory acquisition and test-
ing are performed completely postdrug treatment mea-
sure the persistent, long-term effects of exposure to
MDMA. Most of the learning and memory studies
reviewed here were performed in this manner, a total of
51 experiments, and all tested doses of 3 mg/kg or
greater. Only 15 experiments found that MDMA con-
sistently produced postdrug impairments in learning
and memory, and another 10 experiments found im-
pairments under specific task parameters only. Most
of the experiments, a total of 36, found that MDMA
produced no postdrug impairments in learning and
memory under all/some task parameters. The reasons
for occasional impairments, however, are ambiguous;
there appears to be no clear pattern in terms of
experimental methods.
Overall, the on-drug effects of MDMA on learning and
memory appear to be dose-dependent, with lower doses
producing no effects or enhancements and higher doses
producing impairments. The threshold for impaired
acquisition and retrieval appears to be approximately
3 mg/kg or more, which corresponds to the doses that
are considered atypically high in human users. The dose
threshold for impaired consolidation appears to be
higher, at about 10 or more mg/kg, and there is even
evidence that doses of 2.5–10 mg/kg can enhance
consolidation. The postdrug effects of MDMA on learn-
ing and memory were negligible in most experiments,
even given that these effects were assessed only at doses
of 3 mg/kg or greater.
D. Findings by Species, Strain, Age, and Sex
To analyze findings by the species tested in each
experiment, we focus on the five experiments in mon-
keys, the 19 experiments in mice, and the 65 experi-
ments in rats [pigeons were only used in one study
(LeSage et al., 1993), and no cognitive effects were
found]. Of the five experiments in monkeys, four found
no effects and one found impairments while on-drug but
no post-drug effects. Of the 19 experiments in mice, one
found a mix of enhancements and no effects (depending
on dose), eight found no effects, five found a mix of no
effects and impairments (depending on treatment/task
parameters), and five found impairments only. Of the
65 experiments in rats, 3 found a mix of enhancements
and no effects (depending on treatment/task parameters),
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33 found no effects, 11 found a mix of no effects and
impairments (depending on treatment/task parame-
ters), and 18 found impairments only. In all three species,
the majority of experiments found that MDMA has no
cognitive effects. About 74% of the experiments in mice,
about 72% of the experiments in rats, and all exper-
iments in monkeys found negligible effects at some/all
parameters.
The studies reviewed here tested a wide variety of rat
and mouse strains. Except for the slight trends men-
tioned previously (in sections VI.A and VI.C), there
appears to be no notable systematic differences in
findings between the strains used in the present
studies. Animal age (adolescents and/or adults) also
did not appear to impact the findings. Of the 23 exper-
iments that trained and/or tested adolescent rodents,
one found a mix of enhancements and no effects,
13 found no effects, 2 found a mix of no effects and
impairments, and 7 found impairments. This pattern of
findings regarding adolescent animals generally mir-
rors that of all experiments (see Fig. 9). The majority
of experiments tested male animals, but of the five
experiments that included female animals, four found
no effects and one found impairments. Although this
suggests that MDMA may have less cognitive risk in
females than males, there are not enough mixed-sex
studies to have any confidence in this conclusion.
In all, there appears to be no differences in the
cognitive effects of MDMA between rats andmice, and
if anything, a less pronounced effect in monkeys. We
also did not find any major differences in effects based
on strain, age, or sex.
VII. High Doses and Neurotoxicology of Drugs
of Abuse
An abundance of studies have reported neurotoxicity
ofMDMAand amphetamines, and as has been reviewed
elsewhere, many of these studies exclusively used high
doses (McCann and Ricaurte, 2004). Fundamentally,
toxicology depends on the proper selection of doses
relevant to those used by people, as even commonly
consumed vitamins are readily toxic at high doses. For
example, high doses of vitamin A are readily neurotoxic
and cause birth defects, but we rarely hear calls that it
be controlled or outlawed. Likewise, botulinum toxin is
the most lethal substance known, but is used readily
and safely at appropriate doses (Rietjens and Alink,
2006). In neurotoxicological research on drugs of abuse,
there is an incentive to find neurotoxicological effects;
these kinds of findings lead to more grants and more
publications, while a lack of effects often leads to neither
(Edwards and Roy, 2017). It is therefore natural to use
high doses that are more likely to yield toxic effects.
With a drug likeMDMA that has no establishedmedical
use and is arguably a public health menace, there may
seem to be little cost to arguing it causes brain damage
rather than arguing it does not. However, when a
previouslymaligned drug is argued to have newmedical
value, a proper assessment of its true toxicology is
essential. Even with these factors, we found that a
majority of experiments did not find evidence ofMDMA-
induced cognitive deficits in animals, even at high doses
of 3 mg/kg or greater (Fig. 11). A careful consideration
of the overall findings suggests that the preclinical
literature on MDMA behavioral toxicity may only be
relevant to certain, atypical, habitual users of high
doses, rather than the typical recreational user; those
findings are probably even less relevant to proposed
therapeutic uses, where the drug may be given at low
doses and only a few times.
VIII. Conclusions
This systematic review highlights that doses of less
than 3 mg/kg MDMA, which we believe are appropriate
to model typical human MDMA consumption, do not
seem to impair cognition in animals. At doses of 3 mg/kg
or greater, which model atypical, heavy MDMA use, the
cognitive effects are unclear, as some findings suggest
that these doses produce cognitive impairments while
the slight majority suggest that they still do not influ-
ence cognition. The on-drug effects of MDMA on cogni-
tion have been assessed across awide range of doses and
appear to be dose-dependent. The postdrug effects of
doses below 3 mg/kg have not yet been studied, but
studies on doses of 3 mg/kg or greater reveal mixed
findings that trend toward insignificance. After analyzing
almost 25 years of findings with respect to methodology,
we believe that the preclinical evidence ofMDMA-induced
cognitive deficits is relatively weak.
Previous neurotoxicity evidence suggests that rats,
mice, and non-human primates exhibit vast differences
in sensitivity to MDMA, with non-human primates
showing the highest sensitivity and mice showing the
lowest sensitivity to MDMA-induced serotonergic defi-
cits. These differences are believed to arise from species
differences in MDMA metabolism (Green et al., 2003,
2009, 2012a). Conversely, the present review suggests
that rats and mice do not exhibit differences in sensi-
tivity to MDMA-induced cognitive impairments, and
that non-human primates are possibly less sensitive
than rodents to these impairments. There is also some
evidence of MDMA-induced cognitive impairments in
rats and mice at doses lower than those necessary to
produce neurotoxicity (20 mg/kg in rats, 50 mg/kg in
mice). Together, this evidence suggests that MDMA-
induced neurotoxicity and cognitive impairments may
be unrelated, and active metabolites may not be respon-
sible for the cognitive effects of MDMA.
Our analyses reveal that MDMA may have no effect
on working memory or nonspatial learning and mem-
ory, but the potential to impair spatial learning and
memory and/or fear-motivated learning and memory.
Cognitive Effects of MDMA in Laboratory Animals 445
The most convincing impairments were those induced
by high doses (3–20 mg/kg) in spatial reference memory
and passive avoidance memory acquisition; however,
visuospatial short-term and long-term memory deficits
have not been consistently found in heavy MDMA users
(Laws and Kokkalis, 2007). Our review also suggests
that MDMA has no effect on working memory in
animals across a range of doses, but retrospective
studies have regularly found working memory deficits
in MDMA users (Murphy et al., 2009, 2012; Nulsen
et al., 2010). Human studies use nonrandom assign-
ment and often test extremely heavy users; these
deficits could have been present prior to MDMA use or
may have been the result of very heavy atypical use.
Since low doses (i.e., 1 to 2 mg/kg) of pure MDMA
produce similar pharmacokinetic, pharmacological, and
psychoactive effects in animals and humans (Baumann
et al., 2007, 2009; Green et al., 2009, 2012a) and do not
produce cognitive impairments in animals, we suspect
that low doses of pure MDMA also do not impair
cognition in humans.
To date, most evidence of MDMA-induced neurotox-
icity and cognitive dysfunction has resulted from ex-
treme animal dosing or heavy recreational use. While
we agree that atypical heavy MDMA use may lead to
some neural and behavioral toxicity, there is insuffi-
cient evidence that typical (i.e., low tomoderate)MDMA
use is detrimental to brain structure/function. Factors
such as polydrug use, adulterants, hyperthermia, and
hyponatremia can still increase the potential for ad-
verse effects and are often involved in recreational
MDMA use (Green et al., 2003; Baumann et al., 2007).
Nevertheless, it is unlikely that less than 3 mg/kg of
pure MDMA poses significant danger to neurological
health if administered infrequently and in a con-
trolled setting. Given that MDMA is administered in
this manner during clinical investigations (Mithoefer
et al., 2016), the therapeutic value of MDMA should not
be dismissed due to potential neurological risks. How-
ever, it is critical to note that the margin between
current therapeutic doses (1 to 2 mg/kg) and potentially
memory-impairing doses ($3 mg/kg) is narrow. There-
fore, 3 mg/kg should be considered the absolute limit for
therapeutic dosing, and we recommend exploring even
lower doses (,1 mg/kg).
We strongly suggest that preclinical MDMA re-
searchers become more concerned with the critical
aspect of proper animal dosing. There is considerable
pessimism regarding the validity of allometric scaling
in MDMA research (Baumann et al., 2007, 2009; Green
et al., 2009, 2012a). Accordingly, the administration of
excessively high doses of MDMA to animal subjects is
not appropriate for determining potential toxic effects
in typical MDMA users. Even at high doses, evidence of
MDMA-induced cognitive deficits is relatively inconsis-
tent. Future studies should aim to examine the effects
of low-dose MDMA to reliably model typical human
consumption and to evaluate any potential therapeutic
value.
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